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editorial
The pursuit of human health is, in many 
ways, a never-ending battle. Winning one fight, 
curing one disease, or successfully managing one 
condition simply buys time for the next concern 
to arise. It is sometimes commented that the con-
ditions that consume most of our time, attention, 
and resources in health care are the direct result 
of prior successes in medicine. One hundred 
and fifteen years ago, infections were the lead-
ing cause of death. As we improved our ability 
to combat these maladies, heart disease became 
our primary reason for leaving this world behind, 
followed closely by malignant neoplasms. The 
additional years of life gained when large swaths 
of the population no longer fell victim to influen-
za, tuberculosis, or the latest stomach bug gave 
more time for our coronary arteries to narrow or 
for malignant cells to grow and multiply within 
our bodies.1
This diatribe may sound defeatist, but with-
in the cold reality that medicine will never tru-
ly conquer death lies a rather comforting truth: 
medicine has become quite effective at denying 
our ultimate mortality for a significant period of 
time. Each medical discovery may only delay the 
inevitable, but the time bought can amount to de-
cades. Indeed, though medical advances can only 
take credit for a portion of this change, life expec-
tancy since 1900 has increased by approximately 
30 years in North America.2
The emergence and expansion of geriatric 
medicine in many ways represents the clearest 
demonstration of the triumph of modern health 
care. With many more individuals living so long 
we now need a whole field of medicine, with ded-
icated practitioners, to manage the unique chal-
lenges of growing old and remaining as healthy 
as possible at an advanced age.
It is difficult to overemphasize the impor-
tance of geriatric medicine at this juncture in 
history. The wave of baby boomers has begun 
the transition to retirement and the start of their 
senior years.3 Our health care system is in the 
midst of tackling tough questions on cost and 
sustainability, exploring new models of care and 
compensation, all with care for the elderly as a 
central concern.4 The recent Supreme Court of 
Canada decision on physician-assisted death has 
brought forth a new national conversation on the 
role of dying in medicine and society at large, a 
conversation with particular relevance for the 
elderly.5
It is in this context that the UWOMJ pres-
ents our issue on geriatric medicine. Challenges 
abound in the field of geriatrics. As we meet these 
challenges and, with luck, prove equal to them, 
new issues will arise to take their place. Yet, just 
as the problems posed in geriatric medicine today 
are the result of the successes of the past, so too 
will the problems of the future demonstrate the 
accomplishments of the present. We hope this is-
sue provides a taste of both the unique challenges 
within geriatric medicine, as well as the potential 
solutions moving forward, contributing to an ev-
er-brighter path to old age.
Craig Olmstead
Junior Associate Editor
Medicine’s eternal struggle
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abstract
PURPOSE: To document senior medical students’ experi-
ences in caring for patients with multiple chronic illnesses in 
family medicine clerkship and explore their attitudes towards 
the inclusion of this topic in existing curricula.
METHODS: A cohort of third-year medical students from 
the Schulich School of Medicine and Dentistry at the University 
of Western Ontario were surveyed following their core family 
medicine clerkship. 
RESULTS: One hundred percent of students surveyed par-
ticipated in the care of patients with multiple chronic illness-
es during their family medicine clerkship.  However, only 28% 
percent reported receiving formal teaching on this topic while 
89.5% felt that multimorbidity should be taught at the clerkship 
level. The majority of students surveyed felt comfortable caring 
for this patient population.
CONCLUSION: Patients with multiple chronic illnesses 
are common in family practice.  All third-year medical students 
encountered patients with multimorbidity during their family 
medicine clerkship.  This study contributes to a growing body 
of literature that suggests the need for a shift in medical edu-
cation and health care delivery in order to better serve an in-
creasingly complex patient population. 
introduction
Canadian medical undergraduate trainees enter clerkship in 
either their second or third year and for many this is their first ex-
posure to clinical practice. Primary care educators are challenged 
with introducing medical students to the broad range of topics 
present in family medicine.1 The Canadian Undergraduate Family 
Medicine Education Directors have published the Canadian Shared 
Family Medicine Clerkship Curriculum in an effort to provide 
learners with resources to supplement their clerkship experienc-
es.2 This learning tool provides objectives, reference cards and cas-
es for 23 common presentations in family practice.  However, there 
is no information relating to the management of patients with mul-
tiple chronic illnesses. Multimorbidity is defined as the presence 
of two or more chronic medical conditions within one individual.3 
The prevalence of such patients is increasing, and family physicians 
play an important role in their medical care.3-8 Numerous studies 
have shown that patients with multiple morbidities experience a 
decreased quality of life, worse health care outcomes and lower lev-
el of functional status.4-8 It is important that medical trainees are 
appropriately trained to care for an increasingly complex patient 
population. Medical education and treatment guidelines are based 
on a single-disease model and provide little guidance for the man-
agement of multiple chronic illnesses within one patient.3,6,9,10 Our 
previous work has shown that medical undergraduate educators 
agree that clinical clerks should be exposed to the management of 
multiple chronic illnesses in family medicine training; however, the 
majority of existing curricula do not address this topic.11
The purpose of this study was to document medical students’ 
experiences caring for patients with multiple morbidities and ex-
plore their perspectives on the teaching of multimorbidity in family 
medicine clerkship.
methods
A 12-item, paper-based survey was developed aimed at doc-
umenting students’ experiences caring for patients with multiple 
chronic illnesses during their core family medicine rotation.  Pri-
mary survey items explored students’ attitudes towards receiv-
ing formal teaching on patients with multiple morbidities at the 
clerkship level. Participants were given the opportunity to provide 
further comments on their experiences caring for patients with 
multiple chronic illnesses as well as feedback on the survey in an 
open-ended question. Formal teaching was defined as structured 
learning that takes place in the following formats: lectures, resident 
Multimorbidity in family medicine clerkship
The student perspective
Emily Harrison (Meds 2015)
Faculty Reviewers:  Dr William E Osmun, MD, CCFP (Department of Family Medicine), Dr George Kim, MD, CCFP (Department of 
Family Medicine)
Table 1: Format of multimorbidity teaching in family medicine clerkship, 
choose all that apply (n = 13)
Answer options Response percent Response count
Lectures/rounds 38.5% 5
Topic presentations 15.4% 2
Small-group discussions 30.8% 4
Assigned readings 30.8% 4
Online case modules 0.0% 0
OSCE 0.0% 0
Resident teaching 76.9% 10
Other (please specify) 38.5% 5
Table 2: Do you feel that you have a practical approach to the management of 
patients with multiple morbidities in family practice? (n = 56)
Answer options Response percent Response count
Yes 55.4% 31
No 17.9% 10
Unsure 26.8% 15
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teaching, online modules and assigned readings.  Students received 
surveys following the final assessment of their core family medi-
cine rotation and completed surveys were entered into an elec-
tronic database for analysis. Third-year medical students who had 
completed their family medicine rotation at the Schulich School of 
Medicine and Dentistry between April 2014 and September 2014 
were eligible to participate.  Ethics approval was obtained from the 
University of Western Ontario’s Research and Ethics Board. 
results
Paper surveys were distributed to a total of 63 students and 
57 were returned, giving a response rate of 90%. All participants 
were part of the 2015 class at Western University. Of these, 81% of 
respondents completed their family medicine clerkship in a rural 
setting, while 100% of respondents indicated that multimorbidi-
ty was common in family practice and 100% were involved in the 
care of patients with multiple chronic illnesses during their family 
medicine clerkship. However, only 28.1% received formal teaching 
on the management of such patients. Those who did receive formal 
teaching were asked to list the formats utilized by their preceptors 
during the core family medicine rotation (Table 1). However, of 
those who did not receive formal teaching on multimorbidity, 81% 
indicated that their preceptors discussed the management of pa-
tients with multiple chronic illnesses. Respondents were asked to 
indicate if they felt they had a practical approach to patients with 
multiple chronic illnesses (Table 2). Respondents were also asked 
to indicate on a 10-point Likert scale whether they felt comfort-
able caring for patients with multiple morbidities, 10 indicating a 
high level of comfort and 1 indicating a low level of comfort (Table 
3). The average response was 6.60 (SD = 1.30). Respondents were 
asked to indicate whether multimorbidity should be included in 
formal teaching during the family medicine rotation (Table 4) and 
if they had received formal teaching on this topic in any other core 
rotation during their clerkship training. Internal medicine was the 
most common (48/50), followed by psychiatry (17/50) and surgery 
(10/50). Respondents were given the opportunity to provide any 
further comments about their experiences with multimorbidity in 
family medicine clerkship (Table 5).
discussion
All students surveyed were involved in the care of patients with 
multiple chronic illnesses during their family medicine rotation 
and the vast majority felt that third-year clinical clerks could bene-
fit from formal teaching on multimorbidity. These findings further 
support the literature indicating that patients with multiple chron-
ic illnesses are increasingly common in family practice and that 
medical education fails to address the needs of this patient popu-
lation.3-8,10-11 Respondents indicated that they received formal teach-
ing on multimorbidity in other clinical areas, internal medicine 
(48/50) being the most common. Interestingly, more than half of 
respondents indicated that they felt comfortable caring for patients 
with multiple chronic illnesses in a primary care setting, despite the 
paucity of formal teaching on this topic within the family medicine 
curriculum. It was surprising that the majority of students surveyed 
indicated a relatively high level of comfort in caring for such a com-
plex patient population. However, literature on undergraduate ed-
ucation suggests medical students’ ability to accurately assess their 
own performance and knowledge base is highly variable and often 
inaccurate.12-14 Future studies could focus on senior medical stu-
dents’ ability to self-assess their proficiency in caring for patients 
with multimorbidity.
The responses to the open-ended survey item, while few in 
number, suggest the need for further study on students’ experienc-
es caring for patients with multiple chronic illnesses. Focus groups 
with senior medical students could provide a more complete view 
of their experiences in family medicine clerkship and could be use-
ful in the development of learning tools to aid in the care of patients 
with multimorbidity. 
This study is not without limitations; our survey instrument 
was not previously validated, and respondents commented during 
the survey session that some items were unclear.  We surveyed a 
cohort of third-year students exclusively from Western University 
and therefore our findings may not be representative of the experi-
ence of undergraduate trainees at other institutions. 
Despite these limitations, this study speaks to the need for fur-
ther development in family medicine undergraduate education be-
yond the single-disease model. 
acknowledgments
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Table 3: On a scale of 1-10, how comfortable are you with the management of patients with multiple chronic illnesses? (n = 57)
Answer options 1 2 3 4 5 6 7 8 9 10 Rating average Standard deviation
Response Count 0 0 1 2 10 10 21 9 4 0 6.60 1.30
Table 4: Do you think that third year clinical clerks should be taught an 
approach to the management of patients with multiple morbidities during the 
family medicine rotation? (n = 57)
Answer options Response percent Response count
Yes 89.5% 51
No 1.8% 1
Unsure 8.8% 5
Table 5: If you have any further comments regarding multimorbidity in your 
family medicine rotation, please include them below (n = 6)
It’s difficult to have an approach to multiple morbidities early on and I think 
it is something that comes with more clinical experience.
Seems very vague; not every patient will be the same. How extensive is the 
teaching going to be? Not sure if it’s necessary.
Geriatrics during internal was the only place we really saw multimorbidity 
discussed - it was great, but a bit more would be nice.
IM had formal teaching in multimorbidity in the context of geriatrics.
Multimorbidity is the rule in family. We didn’t learn a pocket approach.
Haven’t done surgery yet so can’t comment.
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introduction
The scenario is all too familiar to the critical care physician 
working in a major teaching centre, or perhaps, even a peripheral 
intensive care unit (ICU) with limited capacity: an elderly patient 
is admitted to the emergency department status post-acute stroke. 
The patient has developed a high systolic blood pressure, a wid-
ened pulse pressure and abnormal respirations, which all point to 
increased intracranial pressure and a potential risk for brain stem 
herniation. A plan is made to admit the patient to the ICU for de-
finitive management, which includes endotracheal intubation, ven-
tilatory support, a hypnotic infusion and an osmotic diuretic like 
mannitol.1 The following morning, the patient’s family arrives and 
there are medical decisions to be agreed upon and executed through 
a family meeting. Up until this point in this patient’s life, there has 
been no formal discussion between family members around the 
topic of end-of-life care.2 No substitute decision maker (SDM) has 
been appointed. This culminates in family members vehemently 
disagreeing on what their loved one would have wanted. The criti-
cal care specialist physician is in a moral quandary. Like most things 
in medicine, effective advanced care planning is a prerequisite for 
success. However, there are always barriers to overcome in the pro-
cess of planning, especially when it comes to death and dying. 
Advance care planning (ACP) results in an advanced directive 
that expresses one’s future preferences for medical decisions when 
one might be incapable of making such decisions.3 The goal of ACP 
is to improve patient-centred care and potentially reduce the in-
tensification of care at the end of life.4 The ACP process is a top-
down modus operandi. The big picture involves making the tran-
sition from living to dying as painless as possible from every facet: 
medical, physical, emotional, spiritual and religious. Unfortunately, 
these psychosocial needs tend to be forgotten in the early stages of 
managing a patient in critical condition. From a medical perspec-
tive, the ICU was developed in the mid-20th century to facilitate 
invasive monitoring and medical intervention to those critically ill 
or injured patients. Critical care medicine burgeoned into a mecca 
of technological and life-saving advancements.5 As a direct conse-
quence of the development of the ICU, some physicians have pro-
posed that Western society has overmedicalized the experience of 
death and dying. Rather than dying at home surrounded by friends 
and family, the elderly have been wasting away and dying in a sterile 
hospital setting.6 The idea of extending life without consideration 
for quality of life has been a topic of contention in the management 
and allocation of ICU-specific resources. Canadian physicians are 
having to come up against the harsh reality that these resources are 
limited. Being cognizant of this, physicians need to overcome their 
inherent paternalistic instinct to keep a patient alive using invasive 
monitoring, vasopressors and mechanical ventilation. Failure to 
identify the point where medical intervention can unintentionally 
prolong patient suffering is a disservice to the patients and their 
families. 
discussion
Patients who are terminally ill consistently identify their top 
priorities as avoiding suffering, being with family and not becoming 
a burden to others, but SDMs often do not realize this.2 An exam-
ple to illustrate this would be a patient with heart failure and un-
derlying arrhythmia that resulted in the placement of an internal 
defibrillator/pacemaker. The patient’s condition has deteriorated 
and the patient is admitted to hospital for medical management. 
Over the last few days of the patient’s life, the family watches their 
loved one progress through the stages of dying. Intermittently, the 
defibrillator fires, causing discomfort to patient and family alike. 
Despite this, the patient’s husband as her SDM refuses to deacti-
vate the defibrillator because he does not want to be responsible for 
killing her. Herein arises the issue of education surrounding end-
of-life care and decision making facilitated by an open dialogue be-
tween all parties involved.
ACP at its core is meant to be a process that facilitates commu-
nication and engages the participant in ongoing reflection.4 Ideal-
ly, ACP involves members of the healthcare team, family members 
and loved ones. A large barrier to the process is the unwillingness 
of some patients to engage in these discussions, because they are 
forced to face the gravity of their illness and prognosis. Converse-
ly, physicians often avoid the topic because their paternalistic in-
stinct hopes to shield the patients from the harsh reality of their 
mortality. While there is a certain degree of emotional upset that 
is bound to occur, most patients when offered a chance to discuss 
their wishes have found such conversations empowering.7,8 In mod-
ern medical practice, a patient-centred approach is emphasized and 
valued highly. However, it may be inappropriate to initiate ACP dis-
cussions at the onset of terminal illness. In doing so, we may be in-
deed asking the patient to predict the individual course of his or her 
disease process. This violates a core tenet of patient-centred care: 
that pathology is not experienced on a universal level by all. Rather, 
illness is defined as a unique experience within a biopsychosocial 
model that includes not only scientific fact, but humanistic factors 
like emotional and cultural differences.  
Recent research at the Schlegel Institute for Aging at the Uni-
versity of Waterloo has provided some valuable insight to assist in 
guiding the patient experience in preparing for death and dying. 
Advanced care planning
A patient-centered approach to end-of-life care
Konstantinos Alexopoulos (Meds 2016)
Faculty Reviewer:  Dr Ravi Taneja, MD, FRCPC (Departments of Anesthesiology and Critical Care)
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Less than half of those Canadians interviewed had discussed their 
preferences for end-of-life care with someone. An overwhelming 
majority believe that these discussions should be had with a family 
member. Most striking is that most Canadians believed they should 
think about or at least discuss end-of-life care while they are in good 
health.9 The barrier between patient and physician seems to be a 
problem of initiating the discussion in a manner which causes the 
least amount of stress for the patient.10 Yet, the physician requires 
an appropriate and a comprehensive strategy to be able to approach 
these discussions. There is no effective check-list approach to ACP. 
There exist some forms of checklist to facilitate discussion. How-
ever, death is shared universal event that is experienced very dif-
ferently amongst individuals and their families.8 Successful ACP is 
reliant on a shared approach of open and honest communication 
between physician and patient.11 
Critical care physicians often engage in family meetings and 
are perceived to have some degree of competence in eliciting pa-
tients’ wishes and facilitating decisions during the end-of-life peri-
od. The checklist approach to family meetings is one that does not 
consider individual patient experiences or prior knowledge of their 
disease and medical interventions like invasive monitoring and 
mechanical ventilation. Research by Scheunemann et al examined 
transcripts of 71 recorded family meetings. The findings suggest 
that a patient’s values and preferences are explored poorly in dis-
cussion with surrogates. Patient preferences were not discussed at 
all in 30% of family meetings. Values like independence, known to 
be highly important to patients, was not discussed in 88% of those 
meetings. Yet, clinicians made explicit recommendations in 61% of 
conferences. The study has obvious limitations, so the results can-
not be extrapolated to all patients and every ICU setting.11,12 The 
study was performed in two ICU settings in California. The authors 
purport that they observed younger physicians who specialize in 
internal medicine or neurology. The Hawthorne effect can also not 
be excluded. These physicians knew they were being observed for 
the purpose of study. Thus, the variety in physician behaviour and 
approach was not fully captured in this study. What can be inferred 
is the fact that physicians may not always be considering their pa-
tients’ wishes and values.12
conclusion
The shared care model of ACP, between patient and physician 
is something that needs to be examined further and expanded upon. 
Clinicians may not have elicited patients’ wishes because of time 
constraints or a fear of upsetting the patient. Patients may be fearful 
to initiate the conversation and are simply waiting for a trigger to 
come along. In the context of patient-centred care, patients present 
with an issue and it is the responsibility of the clinician to assess and 
manage the complaint. If healthy patients were regularly prompted 
to think about end-of-life care in cooperation with their health care 
provider, it is likely that we would be better able to preserve some 
dignity in death by avoiding costly and unnecessary hospitalization.
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abstract
The volume of geriatric surgery is expected to increase dra-
matically by 2020, requiring a more widespread appreciation 
of the unique risks and challenges of anesthesia in the elderly. 
Changes in pharmacokinetics along with age-related chang-
es in organ function have important implications for patient 
monitoring and dosing of anesthetic, analgesic, and sedative 
medications. Preoperative screening for risk of postoperative 
morbidity is improved with an assessment of activities of dai-
ly living, and regional anesthesia may be considered to reduce 
the risk of postoperative delirium, although this remains con-
troversial. Specific homeostatic parameters should be closely 
monitored in the perioperative period. The approach to anes-
thesia in geriatric patients should not be merely extrapolated 
from younger patients, and further evidence specific to geriat-
ric anesthesia will improve surgical outcomes.
It is no secret that our population is aging, with an estimated 
50% increase in the over-65 population by 2020 from 2001. Older 
patients also have invasive procedures at nearly quadruple the rate 
of younger patients, particularly in ophthalmology and cardiology 
(9- and 2.5-fold, respectively).1,2
Across a variety of surgical procedures, a linear increase in the 
absolute risk of surgical morbidity is observed with age, increasing 
from 11% in 20-29 year old patients to 49% in octogenarians. Sur-
gical mortality increases exponentially with age, with a dramatic 
increase from the fifth decade of life, reaching 6% in octogenarians 
as compared to 0.4% in patients in the 20-29 year old cohort. While 
the prevalence of risk factors is correlated to age, age remains an 
independent risk factor for postoperative morbidity and mortality.3
As human physiology changes with age, it has been widely 
shown that pharmaceutical drugs have correspondingly modulated 
pharmacokinetics. The drugs in the anesthesiologist’s arsenal are 
no exception, and this article will review concerns that the anesthe-
siologist must take into consideration when treating the geriatric 
patient. More specifically, this article will discuss considerations 
for planned surgeries, rather than emergent operations, in order 
to focus on the importance of preoperative screening and proper 
follow-up.
physiological changes of aging
Pharmacokinetic changes in drugs
There are important age-associated body compositional 
changes with implications for pharmacokinetics.   Reduced relative 
water content and increased fat percentage result in a higher se-
rum drug concentration after bolus injection and longer half-lives 
for lipid-soluble drugs.  Declining cardiovascular function can slow 
drug delivery to tissue sites, resulting in a slower onset of action. 
Decreased albumin content and protein binding results in a higher 
volume of distribution of acidic drugs.  The opposite is seen for al-
kaline drugs.4
As the human body ages, gradual deterioration of all body 
systems also results in reduced hepatic and renal metabolism and 
excretion, impaired cardiovascular distribution and disrupted flu-
id homeostasis.  Although the liver and kidneys display minimal 
structural changes with aging, it has been found that P450-depen-
dent oxidation decreases, meaning that hepatically cleared drugs 
(eg propofol) have a longer half-life.4
Pharmacodynamic changes in drugs
Decline in cardiovascular health, especially through stiffening 
of the blood vessels and cardiac decline, is a leading risk factor for 
peri- and postoperative morbidity. Cardiac decline describes dia-
stolic dysfunction and an increasing dependence on sympathetic 
drive and the Frank-Starling mechanism. Increased central nervous 
system dependence of cardiac function often manifests as a marked 
decline in blood pressure with anesthesia induction.4
Inhaled anesthetic agents such as sevoflurane and desflurane 
remain agents of choice for North American anesthesiologists, de-
spite the still-unclear mechanism of action. It is therefore import-
ant to recognize that inhaled drugs have a decreased minimum al-
veolar concentration (MAC) in geriatric patients due to a greater 
sensitivity; whereas the MAC of isoflurane in the pediatric patient 
is 1%, it is 0.25% in the 95-year-old patient. Geriatric patients also 
exhibit a higher sensitivity to opioids and benzodiazepines, so it is 
important for the anesthesiologist to carefully titrate administra-
tion of narcotics to minimize toxicity while maintaining effective 
pain management.4,5
practical considerations in the or
Since geriatric patients are often receiving polypharmaceutical 
treatment, it is important to conduct physiologic optimization and 
to minimize premedications (eg heparin, diuretics). Preoperative 
risk factors (eg hypertension, dyspnea) have been identified to be 
more important than intraoperative events (eg transient hypox-
emia, apnea) in predicting postoperative morbidity.
 While preoperative screening is common practice in most 
centres, it is important to be more thorough with elderly patients 
and to complete a comprehensive history and physical exam.  Many 
abnormal lab values, including anemia, creatinine, and hypergly-
cemia, are less effective than history and physical examination at 
predicting postoperative morbidity.6,7 To that end, a geriatric assess-
ment is recommended for elderly surgical patients; 6 questions re-
garding activities of daily living and instrumental activities of daily 
living have been shown to identify 98.5% of elders with postopera-
tive morbidity (Table 1).8
clinical procedures
Modifications in anesthesia for geriatric patients
Brandon Chau (Meds 2018), Alexander Levit (MD/PhD 2020)
Faculty Reviewer:  Dr Daniel Cuillerier, MD, FRCPC (Department of Anesthesia and Perioperative Medicine)
UWOMJ 84:2 | Fall 2015  Page 11
Perioperative considerations and patient management
Control of body temperature is essential for successful sur-
gery as anesthesia can lead to hypothermia. This effect is further 
pronounced in the geriatric patient because baseline hypothalamic 
function often declines, leading to impaired thermoregulation, es-
pecially with general anesthesia. Since even mild hypothermia can 
lead to infection or myocardial infarction, the anesthesiologist must 
be particularly vigilant with maintenance of body heat in the elder-
ly.9
Because age-related deterioration of renal and cardiac function 
negatively impacts fluid homeostasis, it is prudent to carefully mon-
itor blood pressure when administrating IV fluids and to be watch-
ful for renal overload. It is particularly important to meticulously 
pay attention to water balance, drug dosing, and maintenance of 
normal intravascular volume to keep patients healthy.10 
Changes in pulmonary physiology also result in increased phys-
iologic dead space due to compliant airways, so minute ventilation 
should be increased, and positive end-expiratory pressure can also 
be considered. Nasal cannulas are also indicated for virtually all el-
derly patients due to declining respiratory function and reserve.9 
As suggested above, the recommended doses for drugs are 
nearly globally decreased in the elderly.  A more comprehensive ta-
ble is provided (Table 2).5
Postoperative monitoring
It is important to be aware of postoperative morbidities such 
as cardiovascular damage and stroke. Intraoperative complications, 
which happen in 20% of geriatric patients, lead to a 6-fold increase 
in morbidity. Hospitalization has also been identified as a risk factor 
for postoperative morbidity, so when possible, outpatient surgeries 
are especially recommended for geriatric patients as this generally 
reduces nosocomial risk in all patients. Finally, since delirium and 
dementia can also occur in the geriatric population after anesthe-
sia, it is important to monitor for changes in mental status during 
follow-up.7,11
conclusion
With the geriatric population projected to increase, com-
pounded with an increasing rate of surgery and of morbidity/mor-
tality risk in patients over 65, it is important to understand the con-
cerns about anesthesia in elderly patients and to appreciate where 
extra vigilance is required.  Due to a global decline in physiological 
function and reserve, drug pharmacokinetics are often severely af-
fected. Declining fluid and temperature homeostasis also imposes 
more responsibilities on the anesthesiologist.  Finally, certain class-
es of drugs, such as opioids and inhaled anesthetics, demonstrate 
a markedly increased potency in the elderly patient, necessitating 
careful titration to avoid toxicity. The field of geriatric anesthesia is 
increasing in importance because extrapolation of knowledge from 
younger patients may not accurately apply to elderly patients. Best 
practice guidelines may need to change as more geriatric-specific 
evidence emerges in the coming years. 
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clinical procedures
Table 1: Sample 6-Item Pre-Op Questionnaire6
Ascending/descending stairs
Urine continence
Walking in a corridor
Bathing
Shopping
Food preparation
Table 2: Recommendations for Dosage Adjustment Consequent to Altered 
Pharmacokinetics and Pharmacodynamics in the Elderly5
Class of drug Dosage adjustment
Barbiturates Modest reduction in bolus dose and infusion rates
Etomidate Reduction of up to 50% in bolus dose
Propofol Reduction of 30-50% in bolus dose and infusion rates
Benzodiazepines Reduction of up to 75% in bolus dose and infusion rates
Opioids Reduction of up to 50% in bolus dose and infusion rates
Non-depolarizing 
neuromuscular 
blocking agents
No reduction in bolus dose, but generally reduced infu-
sion rates depending on the drug
Volatile agents Reduction in inspired concentrations of 6% per decade of age
Local anesthetics Small to moderate reduction in segmental dose
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introduction
Frailty is a term often used by both medical experts and lay-
men, yet defining the concept proves to be more difficult. Frailty is 
not just aging, though its prevalence increases with age.1 A person 
who is frail may show no symptoms of disease, no co-morbidity, nor 
disability, but is more susceptible to rapid decline in the event of 
illness. Then how do physicians track this condition and communi-
cate accurately with colleagues? And what are the implications of 
frailty and its clinical significance?
In broad terms, frailty is a constellational phenomenon consist-
ing of weakness, aging, declining physiologic reserve, and impaired 
cognitive capacity. This increased vulnerability from age-associat-
ed functional decline results in a reduced ability to cope with every-
day or acute stressors.2 Although loosely defined, frailty has been 
found to be a prognostic indicator of recovery after illness, hospi-
talization, and surgery.
definitions
Currently, there are at least 27 different measurements of frail-
ty described in literature, each with its own focus and advantages.3 
Depending on the definition, the prevalence of frailty in people age 
65 or greater is estimated to be around 10.7%.4 It increases with age 
and with chronic comorbid conditions. However, there is currently 
no consensus on a preferred definition. Here we introduce a few 
common ways that physicians characterize frailty.
The Frailty Phenotype (FP) is defined as having 3 or more of 
unintentional weight loss (≥ 10 lbs or 5% body weight per year), grip 
weakness (≤ 20th percentile), exhaustion (self-reported), slow gait 
velocity (≤ 20th percentile), and low physical activity (based on a 
questionnaire).5 It is shown to be an independent prognostic fac-
tor for falls, worsening activities of daily living, hospitalization, and 
death. While FP provides a concrete definition, some of its compo-
nents such as grip strength measurement are more technical. Also, 
the physical activity questionnaire is time consuming, making FP 
less practical for routine clinical use.6 Since then, a variety of more 
clinically friendly tools have been developed. 
One of these tools is the Clinical Frailty Scale (CFS). CFS evalu-
ates the presentation of frailty on a scale of 1 to 7, taking into account 
mobility, assistive devices, energy level, comorbidities, physical ac-
tivity, and functionality.7 A series of pictographs is even available to 
facilitate the diagnosis. A recent study assessed a group of seniors 
using both the CFS and the Frailty Phenotype, and concluded that 
the 2 tools have a high concordance.6 
In general, a frailty assessment involves functional evaluation 
along with other indicators to form a comprehensive picture. The 
“timed up and go” test is a classic motor assessment that involves 
a patient rising from a seated position in a chair, walking 3 meters 
forward, turning around, then walking back to the chair and sitting 
down.8 This test requires both static and dynamic balance and is 
closely related to mobility in everyday life. Moreover it is quick and 
can be easily included in the comprehensive geriatric exam. 
Combining motor function and other indicators, a variety of 
frailty indexes have been proposed, including one outlined in the 
Survey of Health, Aging and Retirement in Europe (SHARE), a pop-
ulation-based longitudinal study.  The criteria include reported fa-
tigue, low appetite, weakness, observed gait (walking without help, 
with help, chair-bound, bed-bound, unobserved), and low physical 
activity. The SHARE frailty instrument also correlates with overall 
mortality.9 
pathophysiology
One of the hallmarks of frailty is a decline in physiologic re-
serve. A number of systems are affected, such as the musculoskel-
etal, endocrine, immune systems, and the brain.10 Sarcopenia, for 
instance, directly contributes to the decline in functional ability.11 In 
the endocrine system, changes in insulin-like growth factor (IGF), 
sex hormone, and cortisol secretion are also associated with frail-
ty.12 Cognitively, frailty is associated with a higher incidence of mild 
cognitive impairment in the elderly.13 
Moreover, frailty is an inflammatory state.14 The frail elder has 
chronically elevated levels of inflammatory markers compared to 
robust older adults. Interleukin 6 and C-reactive protein are pres-
ent in low grade inflammation, and are associated with morbidity in 
the geriatric population. But it is uncertain whether frailty leads to 
inflammation or vice versa. This inflammation leads to a catabolic 
state contributing to weight and muscle loss.15 Furthermore, anti-
body responses to vaccinations are reduced, leaving frail patients at 
an increased risk of contracting infections such as influenza.16  
The causes of these physiological changes are complex. Frailty 
upsets the delicate balance of homeostasis, leading to loss of phys-
iologic reserve. With more research into the pathophysiology of 
frailty, biological markers may potentially be combined with func-
tional assessment to evaluate frailty in the clinic.17
implications
Slow gait speed, low physical activity, weight loss, and cogni-
tive impairment are associated with chronic disability, long-term 
nursing home stays, and mortality.18 Hospitalized patients who are 
frail have increased risk of developing delirium.19 Preoperative frail-
ty is associated with higher postoperative complications, length of 
stay, and discharge to assisted-living facilities.20 Kidney transplant 
recipients who are frail have delayed graft function.21 Thus, assess-
ing frailty is important in planning elective procedures and during 
the course of hospital stay. It can also serve as a prognostic factor 
for expected patient recovery. 
Frailty
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After a patient is recognized to have frailty, there are ways to 
slow its progression. Currently, medications and hormone sup-
plementations are not recommended,22 but avoiding polypharma-
cy is frequently beneficial.23 Interventions mainly involve lifestyle 
changes and supportive care.24 For example, nutritional counselling 
and micronutrient supplementation can help maintain weight.25 
Resistance exercises can be prescribed to strengthen hips and 
knees.24 Finally, home visits, social support, and outpatient care to-
gether construct a holistic patient centered environment for frail 
patients.26
conclusion
Frailty is an important condition affecting seniors, and contrib-
utes to morbidity and mortality during the course of medical care. 
There are many definitions of frailty. However, there is not yet a 
consensus for any single set of diagnostic criteria.27 We must recog-
nize that frailty is a complex medical condition. The various criteria 
assess this condition from different angles, such as muscle strength, 
cardiovascular status, and activities of daily living. Physicians need 
to weigh and balance these perspectives and keep in mind the larg-
er picture when making clinical decisions for their patients, such as 
whether or not to perform elective surgery. In an aging population, 
physicians will be taking care of an increasing number of elder-
ly patients. The recent increase in literature on frailty reflects its 
growing recognition and importance. Thus, an understanding and 
appreciation of the evaluation, impact, and management of frailty is 
critical to future health care in Canada and around the world. 
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ethics & law
background
Geriatric patients are often underrepresented in clinical re-
search,1 in part due to underrecruitment and to their often arbitrary 
exclusion from trials.2,3 Recruitment is especially difficult in older 
patients with language barriers, access barriers to leaving the home, 
and diseases that impair decision-making capacity.1,2 The paucity of 
geriatric research is troubling given Canada’s aging population,4 as 
research findings in younger study participants may not be gener-
alizable to older patients.5 This lack of evidence is problematic for 
health care providers, who must decide whether prescribing cer-
tain treatments to older patients is appropriate without the proper 
evidence base.1
Unique ethical and legal challenges exist surrounding recruit-
ment of incapacitated older patients, specifically within the context 
of dementia. Between 44% and 67% of patients with mild-to-mod-
erate dementia do not have the decision-making ability to consent 
to participating in research, and all patients with severe dementia 
are considered incapacitated.6 However, their inclusion in research 
is essential to furthering investigators’ understanding of demen-
tia. For example, both cerebrovascular and cardiovascular disease 
(CVD) have been associated with cognitive decline; without the 
participation of patients with late-stage dementia, researchers can-
not thoroughly investigate how CVD influences the progression of 
cognitive decline or, contrarily, how dementia may put a patient at 
risk of CVD.7 This article explores how older adults with dementia 
may be included in clinical research while protecting these older 
adults from coercion or harm.
legal standards for decision-making
In considering the legal challenges of geriatric research in in-
capacitated older populations, it is important to first define capac-
ity. Although not a universal definition, the “four abilities model” 
devised by Appelbaum and Grisso describes four criteria to define 
legal standards of capacity: being able to reason about options, com-
municating a decision, understanding the context of that decision 
and appreciating its foreseeable consequences.6,8,9 Many patients 
with dementia do not meet these standards of capacity and are 
thus unable to provide consent themselves when participating in 
research.6,10 In Canada, the Tri-Council Policy Statement (TCPS) 
on Ethical Conduct for Research Involving Humans dictates that 
only a substitute decision-maker (SDM) who is not part of the re-
search team may authorize an incapacitated adult’s participation in 
research.11 Although the SDM’s consent is required for participa-
tion, the patient’s dissent (ie objection) to participation overrules 
the SDM’s decision.11,12 Therefore, investigators should provide in-
capacitated patients with as much information about the trial as 
patients’ understanding will allow, in an effort to obtain their af-
firmative agreement, otherwise known as their assent.13 In the con-
text of dementia, assent is defined as the ability to express a choice 
and at least a minimal understanding of the information provided. 
The inability to communicate a choice and thereby provide assent 
does not preclude a patient with dementia from participating in re-
search; however, assent is required for patients who have this abili-
ty, and dissent to participation is unequivocal.12
The TCPS also states that incapacitated adults may only be re-
cruited for research specifically requiring their participation (eg an 
Alzheimer’s disease treatment study) and involving either minimal 
risk or risk that is outweighed by potential direct benefits.11 These 
standards parallel the protective measures in place for paediatric 
research.14 There is no clear threshold of when potential risks out-
weigh direct or indirect benefits. Thus, to balance scientific inquiry 
with protection of patients, review of protocols for research of inca-
pacitated older adults must consider broad risk-benefit categories, 
and protocols with no anticipated benefits to study participants re-
quire more conservative risk-benefit analyses.10
ethical considerations
The decision to include an older, incapacitated participant in 
research must respect that individual’s values and address princi-
ples of beneficence, non-maleficence and justice.15,16 There is dis-
agreement in the literature regarding the most ethical approach to 
making this decision. Two commonly considered approaches are 
“best interests” and “substituted judgments”. In substituted judg-
ments, the SDM makes a decision based on what the participant 
may have believed, thereby aiming to respect the participant’s val-
ues and wishes. A concern with substituted judgments is that often 
an SDM may be unaware of the patient’s prior wishes since consent 
to research is not routinely incorporated in a patient’s advance di-
rectives.17
In contrast to substituted judgments, which emphasize the pa-
tient’s prior wishes, “best interests” values the SDM’s opinion on 
what is best for the patient. “Best interests” aims to maintain the 
older adult’s quality of life and avoid unnecessary harm, should the 
intervention pose risks.17 Making this judgment is challenging in 
the case of established treatments and becomes even more so when 
evaluating an experimental treatment with unknown risks and ben-
efits. Another concern with this more paternalistic approach is the 
possibility of the older adult’s previous wishes being disrespected.
With either approach, it is very difficult to determine whether 
a person without the ability to consent would be interested in ther-
apies with potential risks that may prolong life without improving 
quality of life.15-17 However, the potential benefits of this research to 
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patients with dementia cannot be uncovered unless resources are 
justly allocated towards studies involving this population of inca-
pacitated older adults.
future directions and concluding remarks
In the context of research involving older, incapacitated adults, 
be it with dementia or other mentally impairing diseases, the best 
course for recruiting patients is not clear. Inclusion of incapacitated 
participants is essential to enhancing our understanding of demen-
tia and might have direct neurological benefits on these individu-
als.6,10 However, SDMs face the challenge of weighing the risks and 
benefits of clinical research to their relative, often having to specu-
late what their relative’s wishes would be.17 To address this concern, 
interest in research trials should be discussed with individuals with 
early dementia while they are still able to decide for themselves. 
Involvement of incapacitated older adults in research trials 
may also be improved by training research personnel on evaluating 
capacity,6 by avoiding arbitrary upper age limits in protocols and 
by addressing access and transport requirements of older adults.2 
Additionally, expanding academic geriatrics and involving a greater 
number of geriatricians on research boards would help to promote 
geriatric research overall.1
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health policy & economics
In the last 150 years, advances in the field of medicine have ex-
tended the average lifespan in the Western world by over 3 decades1 
and this trend shows no signs of slowing down. If current forecasts 
are accurate, a third of all babies born in the Western world today 
will live past their hundredth birthday.2 A century ago, this demo-
graphic shift had primarily been due to reduced infant mortality 
and better infection control, and this trend has continued more re-
cently due to better management of chronic conditions like cancer 
and heart disease.1 Nearly half of provincial/territorial government 
healthcare spending is allocated to seniors (those 65 years of age 
and older), but our aging population will only cause this proportion 
to increase, likely reaching unsustainable heights.3 This ongoing 
demographic shift will force us to balance economic sustainability 
with the effective care of seniors in hospital, postdischarge, and at 
end-of-life.
A report by the Canadian Institute for Health Information il-
lustrated the current financial burden of seniors on the healthcare 
system quite handily. While adults aged 15-64 cost our healthcare 
system an average $2286 per capita annually, health spending on 
seniors was $10 742 per capita. Furthermore, the financial cost for 
those seniors aged 80 years and over cost the system a staggering 
$18 160 per capita.5 This provides a significant challenge for our 
healthcare system, as it is projected that over the next 25 years, the 
proportion of the Canadian population 65 and over will jump from 
14% to 25%.4 
Although longevity is expensive, technically speaking, it is not 
age itself that increases healthcare expenditure but rather the num-
ber of chronic diseases an individual possesses, which tend to rise 
with age. Indeed, between 50-60% of seniors suffer from three or 
more chronic diseases, compared to 15-30% of those aged less than 
65 years.6 Most chronic conditions are self-managed by patients and 
their families at home until patients are typically in their late 70s. 
Unfortunately, while hospitals are often exceptional at treating pa-
tients with acute conditions, their management of patients who re-
quire chronic care is often fraught with inefficiency, fragmentation, 
and poor outcomes.3,7
Alternatively, long-term care (LTC) facilities are structured 
around the rehabilitation and continued management of patients 
with these chronic and often deteriorating conditions.8 They are 
institutions designed to fill the gaps created by our hospital-cen-
tric system, yet they are woefully underutilized by policy-makers. 
Though the plan is always to transfer chronic patients to LTC or 
home care, our system is ill-equipped to meet this growing demand. 
In Ontario alone there are 2000 waiting in hospital beds for LTC. 
Of the 1000 of these waiting in acute care hospital beds, three quar-
ters will be placed in LTC within 10 months; however 15% will pass 
away while on the wait list. And this demand-supply mismatch is 
only getting worse with the median wait time tripling from 2005 to 
2012.9 What makes this issue even more frustrating is that one day 
in a hospital costs the province approximately $1000, while com-
parable LTC costs only $137.10 and homecare just $55.11. Focused 
investment in LTC would not only improve patient outcomes for 
the chronically ill, but also save the healthcare system money by 
freeing up acute care beds, thereby allowing hospitals to better treat 
those with acute illness.
Seniors with chronic needs occupying acute care beds is a 
ubiquitous problem in our healthcare system that will only worsen 
as our population continues to age. The term “Alternate Level of 
Care” (ALC) describes this phenomenon—patients who have com-
pleted the acute phase of their management in hospital, yet contin-
ue to occupy an acute care bed. Currently, seniors comprise 40% 
of acute hospital stays in Canada, and of the 85% of such stays that 
were designated ALC, nearly half were waiting to be placed in an 
LTC facility.12
At Mount Sinai Hospital in Toronto, a program called the Acute 
Care for Elders (ACE) Strategy has shown great promise as a model 
for streamlining senior care and reducing the number of ALC pa-
tients. The premise of ACE is to implement a higher level of integra-
tion across the multiple modalities of healthcare and social services 
a patient might be receiving across a variety of locations—namely 
the home, community, and hospital. For example, part of ACE in-
volves screening seniors who present to the emergency room for 
risk factors that might predict poor outcomes, then adjusting both 
in-hospital and postdischarge care accordingly. Specialized inpa-
tient geriatric consultation teams manage issues that contribute 
to functional decline, and aim to avoid hospitalization altogether 
if possible. Upon discharge, patients are meticulously followed and 
receive ongoing homecare via partnerships with local organiza-
tions, geriatricians, and geriatric psychiatrists. In just one year, the 
project saw tangible reductions in average length of hospital stay 
and hospital readmission rates, and patient satisfaction with this 
program was polled at 97%.3 The cost and cost effectiveness of the 
resources required to achieve these gains has not been determined 
yet, however.
Studies have shown that within 30 days of being discharged 
from the emergency department, 8% of seniors are either read-
mitted to hospital or die, with an additional 16% returning to the 
ER.13 Integrated care systems such as ACE have been shown to keep 
seniors at home, reducing stress on the healthcare system by de-
creasing the quantity and length of hospitalizations, while simulta-
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neously improving the level of access and quality of care received. 
The first four years of PRISMA, a similar integrated care project 
in Quebec, found a 50% reduction in unmet medical needs, a 20% 
reduction in ER visits, a significantly reduced number of hospital-
izations and a 14% decrease in individuals experiencing functional 
decline.14 Again, the economic sustainability of this program has not 
been established.
It is clear that medicine works best when it is integrated as 
part of a multidisciplinary care system that is organized around the 
needs of the individual, but integration can come in many forms. 
Several studies suggest that case managers may be an invaluable 
tool in facilitating the care of the aging population. These are in-
dividuals (often nurses) who coordinate care from different pro-
viders, ensure that communication is maintained between mem-
bers of the patient’s healthcare team, and educate patients on what 
care they require and how to go about getting it. Furthermore they 
would arrange, coordinate, and oversee the home care for hospital-
izable conditions such as pneumonia, congestive heart failure, and 
COPD. A trial of such a project in Australia involved assigning se-
niors a case manager to oversee their medical care, and resulted in 
21% fewer ER visits and 28% fewer hospital admissions.15  
The nuances of palliative care are another area where the hos-
pital machine seems to fall short. The human condition is in part 
defined by our remarkable ability to hope even in the face of tre-
mendous adversity, even in the face of hopelessness. Broaching the 
subject of palliative care seems to run contrary to our nature, forc-
ing both healthcare providers and patients to address the uncom-
fortable subject of death. However, talking about death demystifies 
it and allows patient preferences to take shape. A randomized con-
trol trial looking at lung cancer patients found that those offered 
palliative care reported improved quality of life at 12 weeks.16 As 
guidelines continue to emerge and healthcare provider education 
improves, this is an area where we will continue to improve.17,18 
There was a time when most people died at home surrounded 
by their families—familiar faces in a familiar environment. Approx-
imately 64% of people die in hospitals while another 12% pass away 
in LTC facilities.19,20 This sadly does not accurately reflect patient 
preferences, as literature shows that the majority of seniors prefer 
to die in their own home.3 
As our population ages, palliative care will give the medical 
profession a tremendous opportunity to put the dignity back in 
dying, allowing people to pass away comfortably and with mean-
ing. Talking about palliative care is a first step. The next step is to 
humanize death by listening to patients, helping them realize and 
articulate their preferences. This will not only improve the quality 
of a patient’s last few months, but also relieve stresses on hospital 
resources, allowing for more effective care of other patient popula-
tions. The availability and flexibility of hospice and palliative home 
care, however, is a major factor in whether it is even feasible for end 
of life to occur at home.
The organizational, economic, and political complexity of im-
plementing such significant shifts in the structure of our health-
care system is daunting, but necessary. As more research is done 
to elucidate the most cost-effective and patient-centered methods 
of accommodating the rapidly changing demographic landscape, 
we expect to see increased funding and manpower being allocat-
ed to expanding LTC facilities. Further, we expect a greater focus 
on the use of programs and case managers that integrate each pa-
tient’s unique mix of medical and social services. We also anticipate 
a greater emphasis on patient preference at end-of-life, and the de-
velopment of better palliative care options. What is certain is that 
Canada’s demographic landscape will see unprecedented change 
in the coming decades as medicine pushes the limits of the human 
lifespan beyond what was previously imaginable. The question that 
remains to be answered is how our healthcare system will manage 
to adapt to meet our aging nation’s rapidly evolving medical needs.
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health promotion
introduction
On February 6th, the Supreme Court of Canada ruled that the 
century-old law condemning assisted suicide was unconstitutional. 
This momentous ruling now opens the door for physician-assisted 
suicide.1 This decision has left many wondering how this will affect 
geriatric, palliative, and end-of-life care in Canada. The ruling has 
been met with much controversy, leaving both physicians, and the 
public unsure how to apply these new rulings to everyday medicine. 
The terms “euthanasia” and “physician-assisted suicide” (or some 
variant thereof ) have been used to describe the potential conse-
quences of the ruling in the media, though these terms should not 
be obfuscated. These are two distinct acts, though this ruling makes 
both permissible. Materstvedt et al defined physician-assisted sui-
cide as “a doctor intentionally helping a person to commit suicide 
by providing drugs for self-administration, at that person’s volun-
tary and competent request.”2 Conversely, euthanasia is outlined 
as “a doctor intentionally killing a person by the administration of 
drugs, at that person’s voluntary and competent request.”2  
history of physician-assisted death
Prior to the Supreme Court ruling, the role of Canadian phy-
sicians in assisted suicide was clear. Criminal Code of Canada 
section 241(b) states “everyone who […] (b) aids or abets a person 
to commit suicide, whether suicide ensues or not, is guilty of an 
indictable offence and is liable for imprisonment for a term not 
exceeding fourteen years.”3 The ethics surrounding physician-as-
sisted suicide, however, are less clear. Many physicians currently 
employ the principle of double effect when taking care of pallia-
tive patients. In essence, double effect is the administration of any 
medication, often narcotics or sedatives, with the intent to palliate 
dying patients even though the administration of these drugs may 
hasten death. Interestingly, in places where physician-assisted 
suicide is forbidden, a “medical death” hastened by palliation is 
typically permissible.4 It is the intention that is most important in 
these cases as the physician is not intending to end life but rather 
chooses to focus on patient comfort at the expense of known drug 
side effects. 
Physician-assisted suicide is inextricably linked to geriatric 
care. In 1997, Oregon legalized physician-assisted suicide. In the 
first year of legal physician-assisted suicide, the median age of 
physician-assisted suicide patients was 69, well within the juris-
diction of geriatrics.5 Of these patients, 86% had cancer, 21% were 
completely disabled, and all were terminally ill. A survey in the 
Netherlands also found that physician-assisted suicide occurred 
predominantly in elderly populations, with a median age of 71. 
Surveys have also shown that elderly people would choose to un-
dergo physician-assisted suicide to prevent becoming a burden to 
their families or others. These patients were quoted as saying, “I 
wouldn’t want to become a nuisance under any circumstance.” 
This provides some qualitative insight into why some healthy old-
er individuals might support medical practices that hasten death. 
In the Netherlands, roughly 17% of patients request physician-as-
sisted suicide because they are “tired of living” and 25% of those 
had no serious disease or no disease at all.6 
Opinions on physician-assisted suicide are divided among 
physicians themselves. Many physicians believe that patients have 
a right to die with dignity, or that patients have a fundamental 
right to autonomy over their bodies. They may also want to help 
to alleviate the suffering endured by their patients with intracta-
ble or terminal diseases. Conversely, many physicians see physi-
cian-assisted suicide as a sign that current palliative care is inade-
quate. They may also believe that physicians should not take on the 
role of executioner. In addition, there is significant concern about 
the potential for abuse of power by physicians.
the supreme court ruling
The Supreme Court ruling has profoundly altered the land-
scape of physician-assisted suicide. The court ruled “prohibition of 
physician-assisted dying infringes on the right to life, liberty and 
the security of the person.” The ruling states that adults who are 
enduring intolerable suffering can consent to ending their own 
lives. The court found that a person’s response to an irremediable 
medical condition was a matter of dignity and autonomy. As well, 
“by leaving people […] to endure intolerable suffering, it impinges 
on their security of the person.” The court also highlighted the fact 
that in jurisdictions that have legislated physician-assisted suicide 
such as Oregon and the Netherlands, the safeguards put in place 
have been effective. In an unusual move, all 9 justices shared credit 
for the ruling, a move intended to lend institutional weight to the 
ruling. Technically, the court has given the federal government 12 
months to write legislation to respond to, or attempt to overturn, 
the ruling. If legislation is not put forth, physician-assisted suicide 
will be in a situation similar to that in which abortion resides: legal 
and left to the medical profession to regulate without government 
oversight.1 
The ruling is not limited to those who might require assistance 
to end their lives, for example patients suffering from amyotrophic 
lateral sclerosis (ALS). It is unclear whether an intractable psy-
chiatric condition might qualify as an “irremediable medical con-
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dition”, since psychological pain has not been addressed directly. 
Instead, it is left up to physicians and lawmakers to determine what 
qualifies as “enduring and intolerable suffering.” Under the new 
ruling, physicians are not compelled or required to help patients 
end their lives, it merely removes prohibitions against it.1 The Ca-
nadian Medical Association (CMA) is presently encouraging phy-
sicians to “follow their conscience” when making these decisions.7
the role of the cma
The CMA has been bracing itself for this decision. For a year 
and a half, the organization has been debating and researching how 
to best handle physician-assisted suicide. As the president of the 
CMA, Dr Chris Simpson acknowledges physician-assisted suicide 
requires physicians to make decisions that go to the “very gut of one’s 
personal ethics and morals.”8 The CMA organized town halls and 
reviewed physician-assisted suicide practices in other countries, 
most notably Oregon and the Netherlands. In August 2014 at the 
CMA’s annual general meeting, members voted 91% in favour of a 
motion to allow physicians “to follow their conscience when decid-
ing whether to provide medical aid in dying.”9 Although this is not a 
formal regulation, it speaks to the general consensus of physicians’ 
opinions on physician-assisted suicide regulations. This resolution 
also signals a changing of policy for the CMA, an organization his-
torically opposed to both euthanasia and physician-assisted suicide.
the changing role of the geriatrician
The emphasis on quality of life in end-of-life care and advanced 
planning discussions suggest that geriatricians will be at the center 
of the physician-assisted suicide discussion. Geriatricians focus on 
holistic, person-centered care, which often centers on quality of life 
rather than its duration. Geriatricians often decrease pill burden in 
patients who would rather take fewer medications, even at the ex-
pense of living for a shorter time, for the sake of fewer side effects.6 
With the emphasis on holistic care and quality of life, physi-
cian-assisted suicide is well within the realm of geriatric medicine. 
The question remains however, how will this new ruling change the 
role of these physicians? It could theoretically alter the landscape 
of the principle of double effect. This ruling may require geriatri-
cians to discuss the option of physician-assisted suicide with their 
patients suffering from irremediable medical conditions. As well, 
physicians will potentially have to engage the families and the sub-
stitute decision makers of their patients, an unquestionably difficult 
conversation. 
On a personal level, this will require geriatricians to grapple 
with their own moral and ethical opinions surrounding physi-
cian-assisted suicide. In a 2014 survey, only 27% of physicians re-
ported that they would be “likely or very likely to participate in” 
physician-assisted dying. To that point, many provincial regula-
tory colleges (in Ontario, the College of Physicians and Surgeons 
of Ontario) require that physicians refer their patients to another 
doctor if they refuse to offer controversial treatments. Historically, 
these treatments have included prescribing birth control and per-
forming abortions. This list may now require expansion to include 
physician-assisted suicide. As Dr James Downar, a palliative care 
physician, explains, “we need to recognize that conscientious ob-
jection in this context can serve as a barrier and we need a very 
robust system to make sure that the physician’s right to conscien-
tious objection does not impinge on the patient’s right to receive 
what would be a legal treatment.”8 This new Supreme Court ruling 
will profoundly alter the practice and culture of geriatric medicine.
conclusions
The Supreme Court ruling declared that aspects of the Crim-
inal Code were unconstitutional with respect to physician-assist-
ed suicide. Prior to this ruling, the role of physicians in these cases 
was clear: they could not participate. With this new ruling, howev-
er, the landscape has changed. Physician-assisted suicide is close-
ly linked to geriatric medicine, as we have seen in Oregon and the 
Netherlands. This new ruling may require that geriatricians discuss 
physician-assisted suicide as an option with their patients. It will 
certainly require geriatricians to reflect on their own beliefs sur-
rounding physician-assisted suicide. This new ruling will reshape 
the practice of geriatric medicine in Canada.
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history of medicine
“In the midst of divisive public debates, we frequently look to history and past epochs to gain guidance and understanding, to ex-plore the genesis of our ideas and practices, and to critically com-pare them with alternatives. — Ezekiel J Emanuel, MD, PhD1the value of historical ideologyThe article from which this idealistic quote was taken from 
was published in 1994; however, one can question whether it was 
ever a habit of human thinking in these past couple of centuries to 
extract guidance from historical occurrences. CS Lewis in his 1955 
book Surprised by Joy denounced the problem of “chronological 
snobbery”, which he defined as “the uncritical acceptance of the 
intellectual climate of our own age and the assumption that what-
ever has gone out of date is on that count discredited.”2 He cau-
tioned of the danger of chronological snobbery in another book. 
The premise was that if human civilization were currently heading 
down the wrong path, it is imperative that we return to that ill-cho-
sen junction and “restart” our history on the right path. However, 
if we ignore the timeline of the previous stages of our journey, we 
risk losing the opportunity to return and start over.3 Quoting now a 
member of our own profession, Eugene F Cordell, President of the 
Medical and Chirurgical Faculty of Maryland in 1904, he lamented 
in an address that “it [was] rare to find the subject [history of med-
icine] even mentioned in the curricula of the medical schools.”4 He 
then attributed this phenomenon to an unhealthy obsession with 
novelty, the unwillingness to make time for reflection, and the in-
creasingly utilitarian and mechanical nature of human mentality.
An appreciation of historical ideology is crucial to a rigorous 
and unbiased study of that branch of geriatric medicine which is 
so ubiquitous and fiercely debated: end-of-life care. This is because 
end-of-life care is not only a medical science, but also a philoso-
phy. It is a value-laden specialty with a complex past. Currently, 
there exist several approaches to end-of-life care, and in every case 
where a patient is enduring his or her last few days, these approach-
es seem to compete for primacy. Proponents of each argue for their 
case, but rarely do they appeal to the historical values behind the 
method. Yet it appears obvious that if we choose to use the term 
“end-of-life care”, we should at least explore the ideas and motiva-
tions of the predecessors from whom we inherited the term. This 
article will discuss 3 approaches to end-of-life care—palliative care, 
life-sustaining therapy, and euthanasia—and illustrate how atten-
tion to the historical evolution of their philosophies can enrich our 
understanding of them. It is hoped that the reader will emerge with 
a deeper knowledge of the rationale behind each approach, as he or 
she explores their genesis and development.
palliative care
Something can be learned about palliative care simply from 
studying its linguistic roots. The term palliative derives from the 
Latin verb palliare, meaning “to cover up” or “to conceal.”5 In the 
context of healthcare, that which is covered up is the pain and suf-
fering associated with end of life. The first record of palliative care 
came from 4th-century Rome, where a Christian matron named Fa-
biola opened her home to pilgrims, the sick, and the destitute.6,7 She 
called her home a “hospice.” During the Middle Ages, it became a 
Christian tradition to take in the sick, poor, pilgrims, and crusaders. 
While none of these primitive hospices cared specifically for the 
dying, they do illustrate that the underlying principle of the earliest 
palliative care was charity.
During the 19th and 20th centuries, hospices specializing in 
end-of-life palliative care opened in France (1842), Dublin (1879), 
and London (1905). But it was not until 1967 that Dame Cicely 
Saunders established St Christopher’s Hospice in London, consid-
ered to be the first modern research and teaching hospice. It was 
founded on three principles: openness, mind together with heart, 
and freedom of the spirit. Saunders was trained first as a nurse, then 
later as a physician. In her early days she cared for a terminally ill 
cancer patient who endured a horrendous measure of suffering be-
fore his eventual death. Touched by their interaction, she came to 
realize the importance of symptom and pain control for the dying. 
At the same time, she saw an even higher need for the dying to come 
to terms with their mortality, a goal which requires both emotional 
and spiritual support.6
These historical revelations led to Saunders’ definition of “total 
pain,” a term familiar to many ears today. This was a new model of 
medical suffering which incorporated the biological, psychological, 
social, as well as spiritual natures of the patient. After completing 
her medical training, Saunders conducted an extensive amount of 
research on palliative care. Her research style consisted mostly of 
listening to patients and studying their narratives, by which she 
was able to pinpoint the individual needs of every patient as they 
lived out their final moments. Our capsule summary of Dame Cic-
ely Saunders’ work shows that many concepts in modern palliative 
care that we take for granted today derive from her philosophy. No 
understanding of palliative care can be complete without a study of 
her life and motivation.6
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life-sustaining therapy and euthanasia
The modern controversies surrounding life-sustaining therapy, 
such as artificial nutrition or hydration and cardiopulmonary resus-
citation, are anything but “new.”8 Due to advancements in medical 
technologies and the management of chronic disease states as early 
as the 19th century and early 20th century, there resulted a shift in 
the culture of medicine from care to cure.9 Life-sustaining therapy 
allowed medicine to keep a patient alive indefinitely in the hopes 
of eventually finding a cure. However, in a desperate attempt at 
cure, palliation of pain and symptoms is often sacrificed, a concept 
recognized even in the 19th century. Simeon E Baldwin, in his 1899 
Presidential Address to the American Social Science Association, 
recounted the tale of a patient, terminally ill with stomach cancer, 
who was sustained by injections of mutton broth. Her agony was so 
great that “her stomach refused to retain anything but a little water; 
and even that caused great pain.”10 
On the other extreme of the end-of-life spectrum is euthanasia. 
Whereas life-sustaining therapy aims to maintain life indefinitely, 
euthanasia seeks to terminate life altogether in the face of suffering. 
Although some may see euthanasia as a recent issue, referring to 
its legalization in 2002 in the Netherlands, the ethics of euthanasia 
has actually been debated for at least several centuries.1,11,12 Familiar 
arguments for euthanasia include that it is a human right born of 
self-determination and that it brings an end to suffering which has 
otherwise no hope of alleviation. In fact, the Flemish Palliative Care 
Federation believes that “euthanasia may […] be part of palliative 
care.”13 Indeed, the philosophy of euthanasia emphasizes pain relief 
and listening to patients’ individual needs, virtues seemingly in line 
with historical values of palliative care.
Notably, much of the continued resistance to euthanasia may 
also refer to historical sources. It has been questioned as early as 
1936 whether euthanasia truly provides biopsychosociospiritual 
support, as it essentially puts the patient that is being “supported” 
out of existence.14 In the Netherlands, 33% of the patients who opt 
for euthanasia do so because of a repulsion of being dependent on 
others.15 However, this seems to defeat the entire underlying princi-
ple of the earliest palliative care, which is that people ought to help 
one another in the name of charity.1
Therefore, modern arguments both for and against euthanasia 
may in fact be rooted in historical philosophy. Proponents advocate 
for pain relief and respecting patients’ personal needs, concepts es-
tablished by Dame Cicely Saunders. Opponents question its true na-
ture and whether it is really designed to support patients at the end 
of life for the sake of charity. However, it is noteworthy that most of 
those who support euthanasia do so with the intent of upholding 
those values that form the foundations of palliative care. As shown 
throughout history, the nature of end-of-life care evolved from an 
innate desire to help, not to ruthlessly eliminate.
concluding remarks
The purpose of this article is not to promote an opinion on 
which approach to end-of-life care is optimal. Rather, it is meant to 
briefly foster an appreciation of the historical purposes and values 
behind each approach. In a day and age where end-of-life care is in-
tensively debated, advocates of each option are eager to voice their 
own opinions based on the most current research and experience. 
However, they often forget that “no generation can bequeath to its 
successor what it has not got” (CS Lewis),16 which implies that our 
ideas and thinking are actually a product and accumulation of those 
that came before us. By studying the quality of their philosophy and 
arguments, we may come to a deeper understanding of both the 
rigour and fallibility of our own. This is imperative in the explora-
tion of end-of-life care, a branch of medicine possessing hundreds 
of years of tradition and change.
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abstract
Community-acquired pneumonia (CAP), most often caused 
by infection with the Gram-positive diplococcus Streptococ-
cus pneumoniae, remains a leading cause of death in Canada 
amongst the elderly. With an aging population in Canada, CAP 
will soon be a significant challenge to the healthcare system 
in this country. In this article, we review the characteristics 
of CAP in the elderly, including its epidemiology, etiology and 
clinical features. We then provide an overview and history of 
pneumococcal vaccines and present current recommendations 
for S pneumoniae vaccination in Canada.
background
Pneumonia, primarily a result of colonization and infection by 
the Gram-positive bacterium Streptococcus pneumoniae, remains a 
dangerous disease with a high mortality rate, especially amongst 
the elderly.1,2 Each year, approximately 200 000 people in Canada 
contract pneumonia2 and around 5000 of those will die from pneu-
monia or complications related to pneumonia.3
Pneumonia can generally be divided into two major catego-
ries: community-acquired pneumonia (CAP) and hospital-acquired 
pneumonia (HAP).4 Nursing homes, where a significant portion of 
the elderly population in Canada resides, are considered communi-
ty settings in the context of community- versus hospital-acquired 
pneumonia.4 We will focus on CAP as a majority of elderly patients 
with pneumonia contract their illness while in a community or in 
nursing homes.1,4
epidemiology of community-acquired pneumonia
The overall incidence of CAP in Canada is estimated to be be-
tween 5.60 and 6.11 per 1000 people.2 A 2-year study at an emer-
gency department in Edmonton, Alberta found that incidence was 
significantly correlated with age.2 Incidence was found to increase 
with patient age for patients over 50, reaching a maximum of 46.39 
per 1000 in patients 90 and older. Incidence was also found to be 
higher in men than in women in patients over the age of 70.2 CAP 
is also the 7th leading cause of death in Canada,5 with an estimated 
mortality rate of between 0.95 and 11.7 per 1000.3
etiology of community-acquired pneumonia
Microbes present in the upper airways routinely enter the low-
er airways. In the majority of cases, they are cleared by specific and 
nonspecific host defense mechanisms, but when this clearance fails 
to occur, pneumonia can result.1,4 Diverse factors that predispose 
individuals to developing pneumonia, and these can be broadly di-
vided into host immunocompromise, exposure to a particularly vir-
ulent respiratory microbe or inoculation with an overwhelmingly 
large microbial load that overwhelms the immune system.4
The diagnosis of CAP in the primary care setting is for the 
most part a clinical diagnosis, and the infectious etiology is often 
poorly established.6 In a review of the literature, it was found that 
a definitive microbial agent was established in only 24-67% of CAP 
cases.6-10 Nevertheless, most studies agree that S pneumoniae is the 
most common infectious agent responsible for CAP, being identi-
fied in 27.4 to 41.9% of CAP cases where a microbial etiology could 
be established.6-10
pneumococcal pneumonia in the elderly
Risk factors
The elderly are at increased risk of developing pneumococcal 
pneumonia.1,2 Specific risk factors that predispose the elderly to 
becoming colonized by S pneumoniae include a depressed immune 
system, increased prevalence of comorbidities, especially lung and 
cardiovascular disease, and difficulty swallowing and aspiration.1
Clinical presentation
The clinical presentation of pneumonia in the elderly differs 
from the “typical” presentation of a young adult with pneumonia.1,11 
In particular, elderly patients with pneumonia tend to display few-
er, or more subtle symptoms, with the authors of one study finding 
an average of 2.9-3.3 fewer reported symptoms in patients over 65 
years of age.11 In particular, there is a lower incidence of fever in el-
derly patients with pneumonia.11 In contrast, there are some clinical 
comorbidities strongly associated with pneumonia in the elderly. 
Most significant amongst these is dementia, which is present in up 
to 41.1% of elderly patients with pneumonia.12
Management
Clinical guidelines recommend that elderly patients with 
pneumonia be managed differently. All elderly patients presenting 
with pneumonia should be assessed for clinical severity, using ei-
ther the CURB-65 score (presence of confusion, BUN > 7mmol/L, 
respiratory rate ≥ 30, systolic blood pressure < 90 and/or diastolic 
blood pressure < 60, age ≥ 65)13 or the Pneumonia Severity Index 
(PSI) developed by Fine et al,14 which is a more detailed guideline 
to assessing severity of pneumonia.
The Canadian Thoracic Society currently does not recommend 
different antibiotic regimens based on age. However, its most recent 
guidelines specifically recommend treating nursing home residents 
with either a respiratory fluoroquinolone alone or with amoxicil-
lin-clavulin and a macrolide as the first-line empiric therapy.13
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streptococcus pneumoniae vaccinology
Overview
Pneumococcal vaccines come in 2 general categories.15,16 First 
are the older polysaccharide vaccines, which consist of purified 
capsule antigens.15,16 These polysaccharide capsule antigens are 
recognized by B cell receptors, resulting in the generation of anti-
capsule IgM antibodies.16 There are a number of distinct drawbacks 
to this strategy, including a lack of T cell antigen recognition and 
resultant lack of isotype switching and production of the IgA anti-
bodies that would be needed to confer mucosal immunity against S 
pneumoniae.16
The newer generation of conjugated pneumococcal vaccines 
consist of capsule antigen conjugated to an immunogenic diphthe-
ria toxoid.15,16 This leads to recognition by Th2 cells and the induc-
tion of isotype switching by B cells and the production of both IgA 
and IgG antibodies, and a stronger memory B cell response.16 In par-
ticularly, production of IgG is thought to be essential in the preven-
tion of invasive pneumococcal disease.16 Unfortunately, the conju-
gated vaccine currently only contains a limited number of serotypes 
as compared to the newest generation of polysaccharide vaccine.
History of pneumococcal vaccines
Pneumococcal pneumonia and its complications were major 
sources of mortality before the widespread availability of antibi-
otics. Mortality rates in the 1920s and 1930s from pneumococcal 
pneumonia and associated bacteremia and meningitis were well in 
excess of 70% in hospitalized patients.15
Early efforts to develop a pneumococcal vaccine began in 1914 
when British immunologist Sir Almroth Wright experimented 
with the use of a crude whole cell vaccine in South African miners, 
amongst whom pneumonia was epidemic.17 By the 1930s scientists 
had advanced to the use of simple polysaccharide vaccines in small 
observational studies.15 These studies paved the way for a number 
of landmark controlled trials on bivalent, trivalent and tetravalent 
pneumococcal polysaccharide vaccines in the 1940s that showed 
for the first time that vaccination resulted in a drop in the incidence 
of pneumococcal pneumonia.18,19
However, by the 1950s the attitude of the public and regulatory 
bodies towards pneumococcal vaccines began to change with the 
widespread availability of antibiotics.15 Pneumococcal vaccination 
was thought to be unnecessary by regulators and it wasn’t until 
the release of a landmark 1964 study by American infectious dis-
ease specialist Robert Austrian showing continued high mortality 
rates amongst patients with pneumonia that interest in a pneumo-
coccal vaccine returned.15,20 Austrian himself was at the forefront 
of S pneumoniae vaccinology, creating the PPSV14 pneumococcal 
vaccine, a polysaccharide vaccine against the 14 most common S 
pneumoniae serotypes of the time, in 1970.21 PPSV14 was adopted 
for widespread use in the United States by 1977 until 1983, when it 
was replaced by the PPSV23 vaccine, which expanded coverage to 
23 S pneumoniae serotypes.15
Currently available vaccines
There are two pneumococcal vaccines currently available in 
the United States and Canada. The first of these is PPSV23 (Pneu-
movax), a polysaccharide vaccine covering 23 serotypes, produced 
by Merck.15,16 PPSV23 has been in used in the United States and 
Canada for several decades and a number of studies of its efficacy 
and safety have been published. A 2013 Cochrane review found that 
available evidence showed PPSV23 was effective at prevention of 
invasive pneumococcal disease (eg bacteremia, meningitis) but not 
pneumococcal pneumonia.22
The second vaccine available is PCV13 (Prevnar-13), a conju-
gate vaccine covering 13 serotypes, produced by Pzifer.15,16 Conju-
gated vaccines for S pneumoniae have been available since 2000 
in the form of PCV7, an early conjugate vaccine that provided cov-
erage of 7 S pneumoniae serotypes. In 2011, PCV7 was replaced by 
the newer PCV13,15 which was made available in the United States 
under the US FDA’s Early Access program, reflecting the changing 
paradigm of the pneumococcal vaccine from being thought of as 
unnecessary by regulators to now being recognized as essential in 
the reduction of pneumonia-related mortality. A large-scale clini-
cal trial in nearly 85 000 patients (the CAPiTA study) sponsored by 
Pzifer showed that PCV13 was 70% effective at the prevention of 
invasive pneumococcal disease and 46% effective at the prevention 
of pneumococcal pneumonia.23
current recommendations on s pneumoniae 
vaccination in the elderly
Current recommendations on vaccination of the elderly against 
S pneumoniae are based on those released by the US Advisory Com-
mittee on Immunization Practices (ACIP).24,25 For individuals 65 
or older, the ACIP has recommended the administration of a sin-
gle dose of PCV13 followed by a single dose of PPSV23 after 6-12 
months.24 There is currently no evidence to suggest that revaccina-
tion with PPSV23 provides additional benefits.25
conclusion
Pneumococcal pneumonia continues to be a major source of 
mortality for the elderly. The development of a vaccination program 
against S pneumoniae has been a major step forward in the efforts to 
mitigate the impact of pneumonia on the health of the elderly.
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medicine & technology
abstract
Bilateral, end-stage, age-related macular degeneration 
(AMD) is a devastating condition of the eye. As the leading 
cause of blindness worldwide in the elderly, it leads to poor 
quality of life. While antivascular endothelium growth factor 
agents are used as front-line treatment for wet AMD, no cur-
rent treatment exists for bilateral, end-stage AMD in Canada. 
The implantable miniature telescope (IMT), approved by the 
Food and Drug Administration in 2010, is a treatment option 
available for those over the age of 65 in the United States with 
stable severe to profound vision impairment (best-correct-
ed visual acuity 20/160 to 20/800) caused by bilateral central 
scotomas associated with bilateral, end-stage AMD. Combin-
ing the fields of engineering and ophthalmology, intraocular 
implantation of the IMT provides improvements in patients’ 
functional vision and quality of life. As a relatively new treat-
ment targeting the elderly, there are strict inclusion criteria as 
well as risks associated with the procedure. However, research 
and continuing development in this field is ongoing to mini-
mize these risks.
age-related macular degeneration
Aging gracefully is a common goal amongst the elderly. Seniors 
over the age of 65 capable of performing activities of daily living 
(ADLs) such as walking and eating, as well as complex instrumen-
tal ADLs (IADLs), including driving and completing housework, 
report having a better quality of life, less morbidity, and less mortal-
ity.1,2 Vision plays arguably one of the most important roles in car-
rying out ADLs and IADLs, but unfortunately vision impairments 
are highly prevalent in the elderly population.2 Bilateral, end-stage, 
age-related macular degeneration (AMD) is one of the most debili-
tating ocular conditions that can dramatically impair the quality of 
life in seniors.3 It is a degenerative disease of the macula resulting in 
a loss of central vision, and central scotomas.4 As the leading cause 
of central vision loss worldwide for the elderly, ahead of cataracts, 
glaucoma, and diabetic retinopathy, AMD affects 0.9, 4.6, and 13.1 
percent of people aged 65 to 74, 75 to 84, and >84, respectively.5 
There are two types of AMD: dry AMD, which is characterized by 
the accumulation of yellow deposits in the macula called drusen, 
and wet/neovascular AMD, which can arise from dry AMD, and is 
characterized by damage to the macula due to neovascularization.3,4 
While genetics may influence the development of wet AMD, cur-
rent hypotheses highlight the involvement of the pro-angiogenic 
molecule vascular endothelial growth factor (VEGF) in this con-
dition.3,6 Both dry and wet AMD can progress to end-stage AMD, 
which presents with bilateral, irreversible macular scars and/or 
large areas of degeneration of retinal pigment epithelium, which 
leads to profound vision loss, increased morbidity and a decreased 
quality of life.7 
current treatments
Several treatment modalities are available for the management 
of AMD. Ranibizumab and bevacizumab are 2 Food and Drug Ad-
ministration (FDA)-approved, anti-VEGF based agents used for the 
treatment of wet AMD.8 Ranibizumab is administered monthly by 
intravitreal injection, and demonstrates an acceptable safety pro-
file.9 Ranibizumab has been shown to halt the progression of wet 
AMD and improve visual acuity by 3 lines on the Early Treatment 
Diabetic Retinopathy Study (ETDRS) scale in 30-40% of patients.10 
However, anti-VEGF agents are ineffective for bilateral, end-stage 
AMD.10–12 An optical option to manage visual impairment is the us-
age of handheld Galilean or Keplerian telescopes. These handheld 
extraocular devices are cumbersome and have a restricted field of 
view, as vision depends more on head and hand movements than on 
natural eye movements.11 Currently, there is no approved treatment 
for bilateral, end-stage AMD in Canada.
implantable miniature telescopes
The implantable miniature telescope (IMT), approved by the 
United States FDA in 2010 for individuals over the age of 65, is a 
treatment for bilateral, end-stage AMD that circumvents the prob-
lems associated with extraocular visual aids.11 This intraocular pros-
thetic is about the size of a pea (3.6 mm diameter, 4.4 mm length). 
It contains wide-angle micro-optical lenses in a Galilean telescope 
design, which when combined with the cornea of the eye, acts as a 
compound telescope. This effect causes retinal image enlargement 
of approximately 2.2 or 2.7 times, enabling an individual to be able 
to distinguish more detail from the visual field.13 The prosthetic is 
surgically placed monocularly into the capsular bag after removal 
of the eye’s lens, protruding 0.1 to 0.5 mm from the pupillary plane.14 
The IMT provides central vision to the eye by providing magnifi-
cation and redirecting light onto the healthy perimacular areas of 
the retina. Coordinated use of the implanted eye for central vision 
and the fellow, non-operated eye for peripheral vision improves 
eyesight for patients with bilateral end-stage AMD, allowing them 
the possibility of participating in both stationary and dynamic ac-
tivities. After the operation, patients are administered prednisolone 
acetate eyedrops for up to 3 months, along with a standardized 
The implantable miniature telescope
Envisioning a treatment for end-stage age-related macular degeneration
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course of antibiotics to facilitate recovery.14 Additionally, patients 
must agree to participate in postoperative visual training with a low 
vision specialist and occupational therapist to maximize their abil-
ity to perform daily activities. The rehabilitation, typically lasting 
6 months to a year, involves training patients to perform tasks at 
different distances and improving hand-eye coordination in both 
stationary and dynamic postures. While this process is challeng-
ing, motivated patients with good psychosocial health and realistic 
goals are able to gain quality of life.
The IMT is well studied, and is the only FDA-approved tele-
scopic prosthetic for the treatment of end-stage AMD.11 One year 
postimplantation, the IMT provides a 3-line or more improvement 
in both distance and near best-corrected visual acuity in 53% of pa-
tients, whereas the untreated fellow/contralateral eye showed im-
provements in 10% of patients.13 Using patient data over a period 
of 12 years, Brown et al showed that IMT implantation in patients 
with bilateral, end-stage AMD resulted in a higher quality of life 
gain compared to controls (fellow/contralateral eye which under-
went cataract surgery), along with a cost-utility of $19 000 USD/
QALY (<$50 000 USD/QALY is considered to be very cost effec-
tive).15
limitations
While the IMT can restore vision to some extent in patients 
with bilateral end-stage AMD, it cannot prevent the macula from 
further deterioration and is not considered a curative treatment.16 
Thus, the IMT is not indicated for patients with active choroidal 
neovascular membranes.16 Another limitation of the IMT is that the 
surgical procedure to implant the IMT demands immense techni-
cal expertise, and therefore carries surgical risk. There has been a 
documented 20% decline in corneal health 3 months postopera-
tively, though damage to the cornea after this period is minimal.17 
Nevertheless, excessive damage to the corneal endothelium may 
necessitate a corneal transplant.17 Due to the risks of performing 
this procedure, the IMT is contraindicated in individuals with pri-
or intraocular or cornea surgery, low baseline corneal endothelium 
cell density, and/or other pathologic conditions affecting the ret-
ina.16 The surgical technique used to implant the IMT, along with 
the prosthetic itself, have undergone revisions to minimize the 
damage that occurs to the corneal endothelium. A recent 2013 study 
showed that the “next generation” telescopic prosthesis required 
smaller incisions to the eye than the current prosthetic, and that the 
resultant improvements in surgical technique led to less corneal en-
dothelial damage.18 With regards to postsurgical events, the IMT is 
contraindicated in patients with cognitive impairment, as this may 
limit their ability to engage in the postoperative rehabilitation that 
patients receiving the prosthetic are required to attend.13,16 In ad-
dition to the rehabilitation process, patients with an IMT will still 
require glasses for further vision correction.16 
summary
Bilateral, end-stage AMD is primarily a disease of the elderly. 
It results in both profound and irreversible visual impairment that 
can limit one’s ability to engage in activities of daily living. The IMT 
is a prosthetic approved by the FDA in the United States for cer-
tain patients over the age of 65 with this condition. Implanted into 
the anterior compartment of the eye, the IMT provides an intricate 
means of improving visual acuity and quality of life for those with 
bilateral, end-stage AMD. Ongoing refinement to both the surgical 
technique and the IMT itself will address concerns over the risk of 
performing the implantation. While the IMT is not a cure, it is an 
improvement on the existing, handheld, extraocular devices used to 
manage end-stage AMD and offers some hope to people living with 
this debilitating condition.
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profiles
Dr Michael Borrie is the Program Director of the South West-
ern Ontario Regional Geriatric Program and past Chair of the Divi-
sion of Geriatric Medicine. Trained in New Zealand and Canada, Dr 
Borrie shared with us his experiences from 30 years of practice in 
geriatric medicine and his current roles as a clinician, researcher, 
administrator, and teacher.  
UWOMJ: Tell us a little about yourself. 
Michael Borrie: I did a degree in biochemistry before entering 
the 5-year medical school training in New Zealand. After medical 
school, we do 2 years as a “house surgeon”, after which we could 
practice family medicine. I wished to pursue internal medicine and 
trained in Edmonton, Alberta and then London, Ontario to special-
ize in geriatric medicine. I met my spouse, Nancy, in my 4th year in 
London. We moved to Dunedin, New Zealand where I did 2 years as 
a research fellow and where we had the first of our three daughters. 
We returned to London in 1985. It was very busy doing mainly clini-
cal service on a 40-bed geriatric rehab unit and I was also one of the 
attending physicians on general internal medicine, doing 1-in-3 call. 
What is special about geriatrics? 
I enjoyed internal medicine. Yet, during the subspecialty rota-
tions, I was looking at the patient through the lens of a single or-
gan system. After stabilizing a heart failure for an elderly patient, 
we were then asked about their arthritis, which we never had the 
opportunity to address. This was not my idea of patient-centred 
medicine and not fully satisfying. This confirmed that I wanted to 
manage older people, multi-system disease and the related com-
plexities, and the field of geriatric medicine was clearly for me. 
Geriatric medicine is special because you can analyze an event 
such as a fall and split out the multiple factors. Often, 6 or more 
different factors combine to cause a person to eventually fall. That 
is the nature of geriatrics. You have a single syndrome: falls, confu-
sion, incontinence or polypharmacy. You can dissect it out and ask 
“what are all the reversible and irreversible factors” and then focus 
on the reversible elements. 
What do you like most about being a geriatrician?
It’s a very satisfying career. Older patients are very appreciative 
of what you do and they’re very respectful. They don’t always fol-
low advice but that’s no different than other patients. I can’t change 
the world but I can do multiple small things for their many complex 
diseases to make a difference to their quality of life and, ultimate-
ly, this is what medicine comes down to—improving the quality of 
someone’s life.
Geriatric medicine deals with multiple chronic diseases and 
their complex interaction. I enjoy the intellectual stimulation of 
understanding a person’s history, as well as the clinical examina-
tion and investigations. I have the luxury of time for a full history, 
examination, and comprehensive counselling that may make a dif-
ference. 
Research has always interested me. There are many research 
opportunities in geriatric medicine from the basic science of indi-
vidual diseases, to clinical trials of novel compounds, to knowledge 
translation that changes patterns of clinical practice and mindful 
clinical care. 
Our division is one of the largest and well-integrated divisions 
across the country. We can support some of us to lead as clinical 
educators or clinician-scientists and everything in between. Each of 
the geriatricians pursues his or her individual strengths and works 
together with allied health professional teams to exemplify best 
practices, care, and education for older adults in our region. 
What are your current responsibilities? 
I do approximately equal amounts of research, administrative 
work, and clinical work, as well as clinical teaching in the outpa-
tient clinic or on the geriatric rehabilitation unit.  
In 1985, I began my career as a geriatrician and by 1995, be-
came the chair of the division. I was one of 4 geriatricians and over 
the next 15 years took on the leadership and administrative role of 
the division. We recruited geriatricians and built the division to 11 
members. As an academic geriatrician, you can develop as a clini-
cian, researcher or clinician-teacher, although it should be noted 
that it is difficult to do both clinic work and research. 
Through my training, interests and opportunities in Canada, I 
have evolved as a clinician-researcher. My research focus was ini-
tially on Alzheimer disease and also on urinary incontinence. In the 
early 1990s, we began new trials in Alzheimer disease and offered 
participation in these clinical trials to patients seen in the Aging 
Brain and Memory Clinic. Over the last 10 years, the focus has been 
on treatments for the amyloid hypothesis and disease modification. 
The trials are more complex lasting several years and require posi-
tron emission tomography imaging for amyloid. 
Can you outline the 2+1 Care of the Elderly option vs 5-year 
training in Geriatric Medicine?
Family physicians with an extra year in Care of the Elderly can 
be very effective physicians in geriatric care. The longer they prac-
tice in geriatric care, the more the distinction between their clinical 
practice and that of a geriatrician narrows. 
The nature of geriatrics
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Care of the Elderly-trained physicians who pursue an academ-
ic career are more likely to have an academic role as educators rath-
er than researchers, unless they have additional research training. 
In community practice they may be the physician lead providing 
consultation or direct management for the elderly patients with-
in a family health team.  They may pursue the Care of the Elderly 
training to develop additional skills for the management of elderly 
patients within their practice. 
As you complete your medical degree, if you are unsure if you 
want a career in family medicine with geriatrics as a focus or a ca-
reer in geriatric medicine, entering an internal medicine program is 
always a good idea. It is easier to switch into family medicine from 
internal medicine than the reverse, and you will be a better physi-
cian for having done additional training in internal medicine. 
In Ontario, of the 130 geriatricians who have completed the 
subspecialty 5-year training in geriatric medicine, half are in aca-
demic centres and half are in community settings.
What are the opportunities and challenges in the future for geri-
atrics? 
My bias is towards the opportunity to prevent, manage and 
treat cognitive impairment. Cognitive impairment is the one con-
dition that threatens a person’s independence. Right now the direct 
and indirect costs due to cognitive impairment/dementia are about 
$10 billion a year.  By 2038, the costs are estimated to be $150 billion 
per year. The biggest driver of direct costs is people with cognitive 
impairment staying in acute care beds and eventually having to live 
in long term care institutions. We could do so much more to prevent 
cognitive decline and its progression. 
Historically, acute care hospitals were built to treat acute ill-
nesses. We can do much better at preventing delirium following 
surgery or medical interventions. There is an irreversible compo-
nent of delirium and patients will deteriorate during an acute care 
admission. This will result in longer hospital stay and drive up our 
health care costs. 
The challenge to future physicians will be developing smarter 
models of care. Technology will affect health care and you will have 
very tech-savvy elderly patients in your practice. For example, as a 
consultant, communication will include e-consults and there will 
need to be different funding models to support this. 
What are your hobbies or personal interests?
My wife and I love to regularly do social and Latin dancing. 
We’ve been doing this since 2005. It’s good for our brain and our 
relationship. I’ve always enjoyed swimming—in high school as a 
competitive swimmer—and now recreationally whenever I have 
the opportunity. 
Any advice for medical students interested in geriatrics?
Take advantage of any opportunities for clinical rotations and 
exposure to geriatric medicine during your training. Get research 
experience in geriatrics, such as the summer research training pro-
gram.
Do you have any thoughts about the recent ruling in favour of 
legalizing physician-assisted suicide (PAS)?
In 30 years of practice, I cannot think of a patient encounter 
where I’ve said that the only option at this point is assisted suicide. 
That may mean that people who would benefit from PAS have nev-
er come to a geriatrician. There may well be a few people for whom 
assisted suicide might be the only option. However, I think one has 
to be cautious about assisted suicide and the potential for a slippery 
slope. If it is thought through very carefully and there are appropri-
ate policies and safeguards in place, there may be some people who 
could benefit. Most people with severe pain are managed appro-
priately and assisted suicide does not have to be considered. As a 
society, we need to protect people who are vulnerable, particularly 
older individuals with disabilities or cognitive impairment, so that 
they don’t feel they have to “move on” and do the honourable thing. 
Fortunately for me, in geriatric medicine, I have never felt the need 
to consider this option. I work with teams and when appropriate 
we aim to provide the best end-of-life care.
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An 84-year-old woman, Doris, is brought to the ER by her 
daughter just after 2300 on a Tuesday night, complaining of a rac-
ing heart beat and palpitations. She is agitated and very uncooper-
ative. Her daughter is worried about how strange Doris is acting. 
She mentions that the patient had an myocardial infarction (MI) 5 
years ago, is diabetic, and takes a number of medications before bed 
at about 2130.
Adults over the age of 65, like Doris, are more likely to visit an 
emergency department than younger individuals.1,2 In addition, 
older adults tend to have more comorbidities, take more medica-
tions (polypharmacy), have higher rates of dementia and other 
neuropsychiatric disorders, and may present with unconventional 
and nonspecific symptoms.2-5 Unsurprisingly, physicians without 
specialized geriatric training report feeling less confident when 
treating older patients in the emergency department compared to 
younger patients.2
Doris is becoming increasingly agitated and confused. On 
examination, her skin appears erythematous, hot, and dry to the 
touch. Her oral temperature is 37.8˚C. She has slight bilateral mydri-
asis. Her respiratory rate is slightly rapid at 20 breaths per minute, 
her oxygen saturation is 99%, and there is no obstruction of her air-
way. With some effort, an electrocardiogram is obtained showing 
sinus tachycardia at 116 beats per minute and her blood pressure is 
slightly elevated at 140/85 mmHg. A fingerstick glucose test shows 
that her blood glucose is 5.8 mmol/L, within normal limits.
anticholinergic toxicity
Doris’ attending physician suspects that she is suffering from 
anticholinergic toxicity due to her classic constellation of symp-
toms. An anticholinergic toxidrome may present when a medi-
cation or poison antagonizes muscarinic receptors throughout 
the body causing a variety of potentially dangerous effects, often 
remembered by the mnemonic “hot as a hare (hyperthermia), dry 
as a bone (anhidrosis), red as a beet (vasodilation), blind as a bat 
(mydriasis), mad as a hatter (delirium and hallucinations), and full 
as a flask (urinary retention).”6 Anticholinergic effects are more 
prevalent in the elderly population, in part due to age-related phar-
macokinetic and pharmacodynamic changes.7-9 Specifically, chang-
es in body composition, including a higher percentage of fat, can 
increase a drug’s volume of distribution and impair elimination of 
certain drugs, including anticholinergics. Furthermore, a drug’s 
half-life may be significantly prolonged in elderly patients due to 
liver or kidney impairment.10 As such, the American Geriatrics So-
ciety recommends that most anticholinergic medications should be 
avoided in older adults.8 Anticholinergic toxicity may result from 
intentional or unintentional poisoning, overdose, and medical over-
sight.6,8,12 In Doris’ case, it is likely that one or more of her medi-
cations is causing this acute reaction, though which drug remains 
unknown. 
Doris is moved into an isolated psychiatric care room in the 
emergency department with her daughter, and her agitation lessens 
thereafter. Her symptoms do not appear to be life threatening, and 
have not worsened since her admission. Complete blood count, 
electrolytes, and arterial blood gases are normal. She continues to 
be monitored closely. 
Treatment of a patient with anticholinergic toxicity varies 
based on symptoms, time since the exposure, route of adminis-
tration, patient delirium and aggression, as well as other patient 
factors. Many cases, such as Doris’, can be treated supportively. 
Activated charcoal can be given to decontaminate the gastric com-
partment if the suspected agent was given orally. It is most effective 
if the instigating drug is known to bind to charcoal and was ingest-
ed within the last hour. In Doris’ case, the drug is unknown and 
ingestion was most likely over an hour ago. The physician also does 
not want to interfere with the absorption of her other medications. 
Physostigmine can be given as an antidote to certain anticholiner-
gic agents in the event of a poisoning; however, it has a number of 
potential adverse reactions including seizures, bradycardia, heart 
block, and bronchospasm.13-15 Doris’ physician is hesitant to start 
any potentially dangerous treatments when her condition appears 
to have stabilized.
prescribing cascade
Doris remains overnight in the emergency department for 
observation. In the morning, her vitals have partially normalized 
and she is no longer agitated. She is able to give a complete history, 
which is significant for an MI 5 years ago, hypertension, seasonal 
depression, type II diabetes mellitus, and osteoporosis. She is cur-
rently taking 13 daily medications for these conditions: proprano-
lol, captopril, low dose ASA, hydrochlorothiazide, metoclopramide, 
fluoxetine, amitriptyline, rosuvastatin, metformin, naproxen, ranit-
idine, alendronate, and a calcium/vitamin D supplement. She has 
also been taking an over the counter (OTC) cold remedy for a per-
sistent cough. She often feels tired during the day and drinks plenty 
of coffee to stay awake. Recently she has had some trouble falling 
asleep. On her daughter’s advice, she took two diphenhydramine 
tablets as a sleep aid. 
Doris’ list of medications is concerning both for its contents 
as well as its length. Many of her medications are clearly aimed at 
managing her current conditions; for example, alendronate and her 
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calcium/vitamin D supplement are most likely related to her oste-
oporosis. However, it is possible that some of her medications are 
simply treating side effects of other medications. This is referred to 
as a prescribing cascade. Prescribing cascades are common in the 
elderly population, particularly when the patient is not educated 
about the potential side effects of a new medication. For example, 
a persistent cough that Doris is treating with an OTC cold remedy 
is a common side effect of acetylcholinesterase (ACE) inhibitors 
such as captopril. Another well known prescribing cascade is the 
use of metoclopramide to treat nausea associated with any number 
of drugs.5,16 Furthermore, Doris’ fatigue may be due to her cardiac 
medications (most likely propranolol), which may influence her 
coffee consumption, which in turn could have necessitated her use 
of diphenhydramine as a sleep aid. The combination of diphen-
hydramine, an anticholinergic sedating H1 antihistamine, with an 
OTC cold remedy (likely containing other anticholinergic medi-
cations, such as chlorpheniramine and dextromethorphan) is the 
most likely cause for her hospitalization.8,10,13 It is recommended 
that diphenhydramine use be restricted in all patients of advanced 
age, except for treatment of severe acute allergic reactions.8 While 
diphenhydramine administration appears to be the precipitating 
factor for Doris’ condition, some of her other medications also have 
anticholinergic effects, notably amitriptyline and ranitidine.8,11–13 
Once Doris’ symptoms have resolved, she is discharged home 
with the recommendation that she follow up with her family doc-
tor. She is instructed not to take any more diphenhydramine or OTC 
cold remedy. 
polypharmacy and inappropriate prescribing
Doris’ case highlights the dangers of polypharmacy, often de-
fined as using more than 5 drugs routinely.9,12,17 Polypharmacy is 
increasingly prevalent in the elderly population, with more than 
25% of Canadian adults over the age of 65 taking more than 5 med-
ications daily.9 Polypharmacy is believed to be due, at least in part, 
to more comorbidities in this age range as well as prescribing cas-
cades, as described above.2,9,12,16 People taking more medications, 
especially the elderly, are at increased risk for adverse drug reac-
tions, which are a significant cause of hospitalization, morbidity, 
and mortality.9,10,18 Up to 25% of older adults report experiencing an 
adverse drug event within the past year, some requiring hospital-
ization.9,18 Notably, many older adults are taking OTC, herbal, and 
dietary preparations in addition to prescription medications, which 
may contribute to drug interactions and side effects,5 as in Doris’ 
case. Nevertheless, polypharmacy itself is not necessarily harmful. 
Patients may be on several medications, all of which are appropri-
ate for their conditions.11,12 What is more concerning in this pop-
ulation is the higher potential for inappropriate prescribing, most 
likely due to the complexity of medication use.12 There are several 
tools available to physicians to evaluate the appropriateness of a 
medication in the elderly population, including the Beers Criteria 
and STOPP Criteria.8,11,12 However, even with these tools in place, 
up to 40% of nursing home residents in one study were prescribed 
at least one inappropriate medication.12,17 
Doris’ family physician notes that several of Doris’ medications 
are being used appropriately to treat her conditions, but there are 
some improvements to be made. The physician suggests replacing 
captopril, an ACE inhibitor, with an angiotensin II receptor blocker 
such as losartan. This may relieve Doris’ cough while still reducing 
her blood pressure. In addition, switching from thrice-daily cap-
topril to once-daily losartan may be beneficial as dosing frequency 
is inversely related to medication compliance.19 The physician also 
suggests that naproxen be replaced with acetaminophen for pain 
control to reduce the risk of salt retention, hypertension, and GI 
bleeds.8,11 It is recommended that Doris’ depression be managed by 
citalopram instead of her current antidepressants, as amitriptyline 
is an anticholinergic agent, and fluoxetine is associated with both 
anorexia and numerous cytochrome P450 interactions.6,8 Finally, it 
is recommended that both ranitidine and metoclopramide be dis-
continued, as both have anticholinergic properties, and metoclopr-
amide in particular is known to precipitate extrapyramidal and par-
kinsonian symptoms in the elderly. These reductions and changes 
in Doris’ medications should reduce her overall anticholinergic 
burden as well as her risk for adverse drug events and interactions.
Polypharmacy, inappropriate prescribing, and adverse drug 
reactions are an exceedingly common yet preventable source of ill-
ness, hospitalization, morbidity, and mortality in the elderly popu-
lation, yet these undesirable outcomes are also preventable in many 
cases.9,18 It is vitally important for physicians to be mindful of these 
issues. Physicians should review the indications and contraindica-
tions for all medications as well as educate their patients on side 
effects of both OTC and prescription medications.
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introduction
Cancer in its many forms is particularly common in elderly pop-
ulations. For females over the age of 80 in Canada, approximately 
2% will have a new diagnosis of cancer each year.1 With thousands 
of types and subtypes, cancer is a heterogeneous spectrum of dis-
eases, each with its own difficulties in establishing a diagnosis and 
an effective management strategy.
The diagnosis and treatment of cancer in the elderly is fraught 
with additional challenges. Symptoms in the elderly may be atyp-
ical or less pronounced compared to younger patients. Seniors 
often have multiple pre-existing conditions and comorbidities in 
addition to their presenting complaint. Most geriatric patients take 
numerous medications, complicating a straightforward diagnosis 
and confounding a simple treatment plan.2-4 Cognitive impairment, 
whether due to pathology or physiological decline, can be a compli-
cating factor, hampering physician-patient interactions.2 Even good 
clinicians can still struggle with the complexities of common malig-
nancies in an elderly patient due to these additional factors. Rarer 
malignancies can be that much more challenging.
Here, we present a case of a patient diagnosed with an excep-
tionally rare hematologic cancer in combination to other comor-
bidities, and explore how the health care team and the family was 
able to collaborate to develop a treatment plan acceptable to both 
parties. 
initial presentation and diagnosis
The patient, CB, was an 83-year-old female retired hairdresser 
who presented with her daughter to her primary care provider with 
a 1-2 month history of left upper quadrant pain. Initially, CB’s pain 
was ill-defined, intermittent, and did not limit her activities, but 
worsened significantly over the few days before the visit.5
On presentation, CB was holding her left side and grimacing in 
pain. CB had an extensive past medical history headlined by mild 
vascular dementia and heart block requiring a pacemaker. She also 
had a history of hypertension, hyperlipidemia, bilateral carotid ste-
nosis, and scoliosis. CB’s medications included aspirin 81 mg daily, 
metoprolol 100 mg twice daily, verapamil 240 mg daily, donepezil 
10 mg daily, ezetimibe 10 mg daily, fluvastatin XL 80 mg daily, and 
memantine 10 mg twice daily. CB’s adult children who lived nearby 
provided assistance with medications and meals during daily visits, 
resulting in good compliance to her prescriptions and reasonable 
nutrition status. CB also retained many of her activities of daily liv-
ing despite her conditions; she dressed, bathed, toileted, and ambu-
lated without assistance. CB was a nonsmoker and consumed 3-4 
beers per day. Despite her dementia CB had some ability to make 
decisions regarding her life and health, relying on her daughter 
more in an advisory capacity on matters needing clarification.5
On physical examination CB did not appear ill. However, the 
exam revealed positive bilateral lymphadenopathy in the neck, ax-
illa, and inguinal regions. Fine inspiratory crackles were noted in 
the left lower base of the lung. Tender splenomegaly, palpable down 
to the left lower quadrant, was also found. No hepatomegaly was 
noted.5
After being admitted to hospital, computed tomography re-
vealed an enlarged spleen occupying two-thirds of the left abdomi-
nal cavity, a small pleural effusion at the left lung base, and enlarged 
lymph nodes along the gastro-hepatic ligament, the porta hepatis, 
the mesentery, and both groins. Complete blood count was remark-
able for a white blood cell count exceeding 70 000 with atypical 
lymphocytes and 20% blasts. Platelets were low at 60 000. A refer-
ral to hematology/oncology was made to investigate possible lym-
phoma or leukemia. Peripheral smears revealed lymphocytes with 
nuclear contour irregularities, cytoplasmic border irregularities, 
and rare nuclear clefts. Prominent nucleoli were lacking in most 
cells. Bone marrow biopsy revealed significantly increased hyper-
cellularity consisting primarily of small lymphocytes. Flow cytom-
etry detected aberrant CD4+/CD8¬ T-cells and was positive for 
clonal rearrangement of the TCR-β gene, suggesting T-cell leuke-
mia. CB was negative for human T-cell lymphotropic virus-1, ruling 
out adult T-cell lymphocytic leukemia. A final diagnosis of T-cell 
prolymphocytic leukemia (T-PLL) was made.5 
t-cell prolymphocytic leukemia
T-PLL is a rare malignancy, typically affecting those 65 or old-
er, with males somewhat more affected than females. Previously 
described as a variant of chronic lymphocytic leukemia (CLL), it 
represents less than 1% of all mature lymphocytic leukemia diagno-
ses.5,6 While most forms of PLL are malignancies of B-cells, T-PLL 
is a malignancy of mature T-cells. It is a particularly aggressive form 
of lymphocytic leukemia, with reported median survival times after 
diagnosis counted in months.7
As T-PLL is quite rare, diagnosis can be difficult. A key feature 
of T-PLL is dramatic splenomegaly, palpable 10 cm below the left 
costal margin in over 80% of patients. Other potential symptoms 
include hepatomegaly, ascites, lymphadenopathy, lymphocytosis, 
pleural effusions, skin lesions, and CNS involvement.6 Further test-
ing typically involves peripheral smears and bone marrow biopsies. 
Immunophenotype features of T-PLL include the presence of CD52 
as well as T-cell markers CD2, CD3, and CD7.7 Genetic features in-
clude clonal rearrangement of TCR genes.8
Typical cancer treatments such as splenectomy, splenic irradi-
ation, leukaphoresis, or standard chemotherapy are largely ineffec-
tive. The primary therapy is a monoclonal antibody called alemtu-
zumab, which targets CD52 and was created to treat B-cell CLL 
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resistant to standard chemotherapy. CD52 targeting causes cancer 
cell lysis by apoptosis through a host effector mechanism. Trials 
have shown remission rates of up to 30 months in patients with 
T-PLL, and several further studies found a median survival time of 
14.8 months with treatment. Hematopoietic stem cell transplanta-
tion is an option for those who achieve complete remission with 
alemtuzumab. Alemtuzumab is associated with serious toxicities, 
particularly myelosuppression. Potential adverse effects include 
severe infections, bleeding crises, and hypersensitivity reactions. 
Regrettably, in all cases the cancer eventually relapses.7,9,10
treatment and follow-up
The health care team engaged in a detailed discussion with 
CB and her family regarding beliefs, quality of life, and the options 
available for palliative and curative treatment. Given CB’s advanced 
age and multiple comorbidities, the likelihood of a negative out-
come from toxicities or side effects was significant. Officially, CB’s 
daughter was the surrogate decision maker. However, she wanted 
CB to be given the opportunity to choose her own treatment, de-
spite the possibility that she may not be fully aware of the risks and 
benefits of treatment. Ultimately, CB opted for chemotherapy with 
alemtuzumab, stating that she “just wasn’t ready to die yet.” A mod-
ified treatment regimen with subcutaneous injections and a slow 
introduction of alemtuzumab was initiated to minimize the poten-
tial for side effects.5
Cost was another challenge faced by the health care team. A 12-
week course of alemtuzumab costs over $240 000. The oncologist 
and CB’s daughter collaborated closely to find outside sources of 
funding to help cover this cost. An infusion center was found sever-
al days later, and chemotherapy was initiated in a timely manner.5
CB tolerated the treatment well, with few side effects. After 6 
weeks of therapy there was a significant reduction in splenomegaly 
and lymphadenopathy, with the white blood cell (WBC) count re-
turning to 2.2, and platelets returning to 176 000. Following the 12-
week treatment CB was discharged on antibiotics as a result of T-cell 
obliteration and followed monthly. At two months post-treatment, 
she was still asymptomatic, with a WBC count of 6.7 and platelets at 
143 000. At three months post-treatment her T-cell counts returned 
to 200 000 and antibiotic therapy was discontinued.5
CB continued to live in her own home post-therapy. She cel-
ebrated her 84th birthday with family and friends, and was able 
to travel to her hometown to visit her remaining family members. 
However, 4 months post-therapy she began to develop recurring 
left upper quadrant pain and splenomegaly. Palliative radiation 
therapy was offered. CB’s daughter, after discussion with the rest 
of the family, refused radiation therapy and other treatment options 
on grounds that it would not bring CB an acceptable quality of life. 
CB was kept in her home with hospice care for pain management 
and end-of-life care. Despite her deteriorating condition, she re-
mained mobile and active until 3 days prior to entering a comatose 
state. She died shortly thereafter with her family at her bedside.5
discussion
The medical side of this case involves an exceedingly rare, but 
notably aggressive form of leukemia. Establishing a diagnosis of 
T-PLL can be troublesome given its rarity and its nonspecific symp-
toms on presentation. Treatment is frequently minimally effective, 
with the main prognostic factor being response to alemtuzumab.7 
As T-PLL is primarily a disease of the elderly, both diagnosis and 
treatment can be challenging. In this case, dementia proved to be 
the main hurdle, as concerns of comprehension by CB were not-
ed by the involved clinicians.5 Nevertheless, physicians should be 
aware of this rather unique form of hematologic malignancy, mind-
ful of its defining features on physical exam and be prepared to 
make appropriate referrals to hematology/oncology when suspi-
cion of T-PLL is high.7
However, at its core this case is worth highlighting for the man-
ner in which end-of-life discussions occurred. In an aging society, 
the strategies for addressing terminal illness in the context of cogni-
tive decline become increasingly important.2,4 This case underlines 
the necessity of including all key stakeholders in the conversation 
about treatment options, including clinicians, patients, and family 
members.2,5 Not every malady is curable, but all patients can feel 
cared for by their medical team.
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